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Abstract 
 
Left ventricular hypertrophy (LVH) is more frequently associated with LV dilatation 
and systolic chamber dysfunction in males than in females. The mechanisms of this effect are 
uncertain. As excessive adrenergic stimulation may be responsible for LV dilatation and 
systolic chamber dysfunction in hypertension, in my dissertation I aimed to assess whether 
gender determines the adverse effects on LV chamber remodeling following 6 months of 
daily β-adrenergic receptor (AR) stimulation (isoproterenol [ISO] at 0.04 mg.kg-1day-1) in 
spontaneously hypertensive rats (SHR). LV dilatation was assessed in vivo from LV end 
diastolic diameter (EDD) (echocardiography) and ex vivo from the volume intercept at 0 mm 
Hg pressure (V0) of the LV diastolic pressure-volume relationship (isolated, perfused heart 
technique). LV systolic function was determined in vivo from LV endocardial fractional 
shortening (FSend) and ex vivo from the slope (LV end systolic elastance [LV Ees]) of the LV 
end systolic pressure-volume relationship (isolated, perfused heart technique). As compared 
to saline-treated male SHR (n=13), male SHR receiving ISO for 6 months (n=13) developed 
an increased LV EDD (Male Saline: 6.56±0.20 mm; Male ISO: 7.78±0.29 mm; p<0.05) and 
LV V0 (Male Saline: 0.22±0.01 ml; Male ISO: 0.31±0.02 ml; p<0.05). In contrast, ISO 
administration failed to modify LV EDD (Female Saline, n=13: 6.06±0.15 mm; Female ISO, 
n=12: 6.33±0.15 mm) or LV V0 (Female Saline: 0.17±0.01ml; Female ISO: 0.17±0.01 ml) in 
female SHR. In addition, there was a gender-ISO interactive effect on LV Ees (p<0.05; Male 
Saline: 2268±336 mmHg.ml
-1
; Male ISO: 1623±164 mmHg.ml
-1
; Female Saline: 1910±219 
mmHg.ml
-1
; Female ISO: 2302±230 mmHg.ml
-1
). In conclusion, as compared to female 
SHR, male SHR are more susceptible to the adverse effects of chronic β-AR activation on 
LV cavity dimensions and systolic chamber function. These results suggest that the higher 
prevalence of LV dilatation and systolic chamber dysfunction in males than in females with 
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LVH may be attributed to an increased susceptibility to the adverse effects of adrenergic 
stimulation.  
iv 
 
Declaration 
I, Mhlengi Mthokozisi Magubane, declare that this dissertation is my own, unaided work. It is 
being submitted for the degree of Master of Science of Medicine, in the Faculty of Health 
Sciences, University of Witwatersrand, Johannesburg, South Africa. The work contained in 
this thesis, has not been submitted for any degree or examination in this university, or any 
other university. 
 
................................................................................. 
Mhlengi Mthokozisi Magubane 
 
Signed on the...............................................day of………………………………………2014 
 
I certify that the studies contained in this dissertation have the approval by the Animal Ethics 
Screening Committee of the University of the Witwatersrand, Johannesburg. The ethics 
approval number is 2010/21/04 
…………………………………………………… 
Mhlengi Mthokozisi Magubane 
 
Signed on the..........................................day of.……………………………………… 2014 
 
  
.......................................................                 ....................................................... 
Frederic Michel (supervisor)                Angela J. Woodiwiss (supervisor) 
Date....................................                       Date.................................... 
v 
 
Dedication 
Firstly, I would like to dedicate this research to my mother Nokuphula Euginia 
Khumalo who made sure that I am provided for from the first grade up until the postgraduate 
level. Secondly, I dedicate it to my grandmother Nokuthula Khumalo for lovingly and 
patiently giving me direction in my life; she has played a significant role in my life. Lastly, I 
dedicate this work to my supervisors, Dr Frederic Michel, and Professors Angela J. 
Woodiwiss and Gavin Norton for their endless guidance and support. 
 
 
  
vi 
 
Publications and presentations 
Data presented in this dissertation have been presented in the form of a poster 
presentation at the 41
st
 Annual Conference of the Physiology Society of Southern Africa held 
at the University of Medunsa, September 2013. The title of a poster presentation was “Sex 
comparison of cardiomyocyte apoptosis in Spontaneously Hypertensive Rats that received 
short-term β adrenergic agonist” 
 
Although during the cause of my MSc I learnt the techniques of echocardiography and 
isolated perfused hearts, these are specialized techniques which require a high degree of skill 
which only comes with experience. Hence in the interests of collecting accurate and hence 
meaningful data an expert with 20 years of experience collected these data. Importantly, I 
was responsible for all the daily administrations of isoproterenol and saline vehicles in these 
animals, assisted with echocardiography and the collection of all the rest of the data including 
assessment of cardiomyocyte apoptosis and necrosis.  
vii 
 
Acknowledgements 
I would like to thank my supervisors, Frederic Michel, Angela Woodiwiss and Gavin 
Norton for their endless patience, commitment and invaluable teaching, I will always be grateful. 
In addition, I would like to thank Mr Zwelibi Majola and Ms Margaret Badenhorst for their 
Technical support. 
 
I would also like to thank the Central Animal Services and their professional staff 
members for their guidance and help during the study and the husbandry that they provided 
for the rats used in the present dissertation. I would like to thank my fellow members of our 
laboratory for their assistance and support received during my degree. Finally I would like to 
thank my family and friends for their support during the many hard hours and challenging 
times. 
 
 
 
 
 
 
 
 
 
  
viii 
 
List of Abbreviations 
 
AC  adenylate cyclase  
AESC          animal ethics screening committee 
ANOVA      analysis of variance  
AV  arteriovenous 
beats.min
-1
      beats per min 
BP  blood pressure  
Ca
2+
           calcium  
CaCl2
 
        calcium chloride 
cAMP         adenosine 3′,5′-cyclic monophosphate 
CHF  congestive heart failure 
DNA   deoxyribonucleic acid  
En             slope of the systolic (σ)-strain relation 
FSend           endocardial fractional shortening 
FSmid          midwall fractional shortening 
g           grams 
g.kg
-1
       grams per kilogram 
HF   heart failure 
HR            heart rate 
HRV   heart rate variability 
ISO            isoproterenol 
LV EDD        left ventricular end diastolic diameter 
LV ESD       left ventricular end systolic diameter 
LVED PWT left ventricular end diastolic posterior wall thickness 
ix 
 
LVES PWT   left ventricular end systolic posterior wall thickness 
LVH  left ventricular hypertrophy  
MAPK  mitogen-activated protein kinases 
MI   myocardial infarction  
mm Hg         millimeters of mercury  
mmol.kg
-1
    millimoles per kilogram  
NE  norepinephrine 
NET   norepinephrine transporter 
p value          probability value  
PLB  phospholamban  
RAAS  renin-angiotensin-aldosterone system 
SD             Sprague-Dawley 
SEM             standard error of the mean  
SHR           spontaneous hypertensive rat 
SNS           sympathetic nervous system  
TAC   transverse aortic constriction  
TDT   terminal deoxynucleotidyl transferase 
TG  transgenic   
TUNEL        terminal deoxynucleotidyltransferasedUTP nick end labeling  
WKY        wistar-kyoto 
WT       wild-type 
α  alpha 
β              beta 
  
x 
 
Table of Contents 
Abstract .................................................................................................................................. ii 
Declaration ............................................................................................................................ iv 
Dedication .............................................................................................................................. v 
Publications and presentations .............................................................................................. vi 
Acknowledgements .............................................................................................................. vii 
List of Abbreviations .......................................................................................................... viii 
List of tables ....................................................................................................................... xiii 
List of figures ...................................................................................................................... xiv 
Preface ................................................................................................................................. xvi 
Chapter One - Introduction ........................................................................................................ 1 
1. Introduction .................................................................................................................... 2 
1.1 Cardiac hypertrophy ..................................................................................................... 3 
1.2 Cardiac dilatation .......................................................................................................... 6 
1.3 Cardiac function and the impacts of cardiac dilatation ................................................ 9 
1.4 Gender effects on left ventricular hypertrophy and the progression to heart failure .. 12 
1.5 Role of sympathetic nervous system activation in the progression to heart failure ... 20 
1.6 Gender effects on sympathetic nervous system activation ......................................... 22 
1.7 Gender effects on sympathetic nervous system induced progression to heart failure 24 
1.8 Aim ............................................................................................................................. 29 
1.9 Objectives ................................................................................................................... 30 
xi 
 
Chapter Two - Materials and Methods .................................................................................... 31 
2.1 Experimental protocol for the long-term β-adrenergic receptor stimulation study .... 32 
2.2 Cardiac structure and function: ................................................................................... 34 
2.3 Experimental protocol for the short-term β-adrenergic receptor stimulation study: .. 40 
2.4 Myocardial cellular changes responsible for HF: ....................................................... 40 
2.5 Data analysis ............................................................................................................... 44 
Chapter Three - Results ........................................................................................................... 46 
3.1 Effects of long-term β-adrenergic receptor stimulation and gender on body and heart 
weights .............................................................................................................................. 47 
3.2 Effects of long-term β-adrenergic receptor stimulation and gender on left ventricular 
dimensions in vivo ............................................................................................................ 47 
3.4 Effects of long-term β-adrenergic receptor stimulation and gender on left ventricular 
systolic chamber function ................................................................................................. 51 
3.5 Effects of long-term β-adrenergic receptor stimulation and gender on left ventricular 
intrinsic myocardial systolic function ............................................................................... 53 
3.6 Effects of short-term β-adrenergic receptor stimulation and gender on body, heart, 
left and right ventricular weights ...................................................................................... 58 
3.7 Effects of short-term β-adrenergic receptor stimulation and gender on necrosis and 
apoptosis ........................................................................................................................... 58 
Chapter Four - Discussion ....................................................................................................... 61 
4.1 Main findings of the present study ............................................................................. 62 
4.2 Uniqueness of current study ....................................................................................... 62 
xii 
 
4.3 Comparisons with previous studies ............................................................................ 63 
4.3.1 Gender influence on the progression from concentric left ventricular hypertrophy to 
dilatation ........................................................................................................................... 63 
4.3.2 Gender influence on the progression to systolic dysfunction in response to pressure 
overload ............................................................................................................................ 66 
4.3.3 Gender differences on cardiomyocyte apoptosis and necrosis ................................ 70 
4.4 The potential clinical importance of the findings of the present study. ..................... 71 
4.5 Limitations .................................................................................................................. 72 
Conclusions ...................................................................................................................... 73 
Chapter Five - References ........................................................................................................ 74 
 
 
  
xiii 
 
List of tables 
Table 1.1: Summary of animal studies reporting on the effects of gender on the progression 
from left ventricular hypertrophy to heart failure. ................................................................... 14 
Table 1.2: Gender effects on sympathetic nervous system induced progression to heart failure
.................................................................................................................................................. 26 
Table 3.1: Effects of long-term β-adrenergic receptor stimulation and gender on body, heart, 
left ventricular, right ventricular weights in male and female SHRs. ...................................... 48 
Table 3.2: Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular dimensions as assessed in vivo in male and female SHRs. ................................... 49 
Table 3.3: Effects of short-term β-adrenergic receptor stimulation and gender on body, heart, 
left and right ventricular weights in male and female SHRs. .................................................. 59 
 
 
  
xiv 
 
List of figures 
Figure 1.1: Diagrammatic representation of changes in the left ventricular end diastolic 
pressure-volume relationship in cardiac hypertrophy. ............................................................... 5 
Figure 1.2: Example of the left ventricular end diastolic pressure-volume relationship ........... 8 
Figure 1.3: Diagrammatic representation of changes in the slope of the developed pressure-
volume relationship (upper panel) and the stress-strain relationship (lower panel) ................ 11 
Figure 2.1: Summary of rat groups in the long-term β-adrenergic receptor stimulation study.
.................................................................................................................................................. 33 
Figure 2.2: Representative example of an M-mode echocardiographic image of the left 
ventricle in a Spontaneously Hypertensive Rat. ...................................................................... 35 
Figure 2.3: Representative example of the experimental setup for the isolated perfused heart 
apparatus. ................................................................................................................................. 38 
Figure 2.4: Diagrammatic example of derived diastolic and systolic (developed) pressure-
volume curves (right panel). Representative example of typical recordings obtained for 
diastolic and systolic pressures in isolated, perfused heart preparations (left panel). ............. 39 
Figure 2.5: Summary of rat groups in the short-term β-adrenergic receptor stimulation study.
.................................................................................................................................................. 41 
Figure 2.6: Representative myocardial tissue sections stained with Van Gieson’s stain for 
necrosis. ................................................................................................................................... 43 
Figure 2.7: Representative examples of cardiac tissues sections stained with haemotoxylin 
and eosin (A) and TUNEL (B & C) after 1 week of injection with isoproterenol (200X 
magnification microscope)....................................................................................................... 45 
xv 
 
Figure 3.1: Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular end diastolic diameter (LVEDD) in male and female SHRs.. ............................... 50 
Figure 3.2: Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular chamber volumes ................................................................................................... 52 
Figure 3.3: Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular systolic chamber function ...................................................................................... 54 
Figure 3.4: Effects of long-term β-adrenergic receptor stimulation on left ventricular systolic 
chamber function as indexed by pressure-volume relations. ................................................... 55 
Figure 3.5: Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular intrinsic myocardial systolic function.................................................................... 56 
Figure 3.6 : Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular intrinsic myocardial systolic function.................................................................... 57 
Figure 3.7: Effects of short-term β-adrenergic receptor stimulation on pathological score 
(necrosis) shown in the upper panel and apoptotic cardiomyocyte (lower panel) in male and 
female Spontaneously Hypertensive Rats.. .............................................................................. 60 
 
  
xvi 
 
Preface 
Heart failure is a disease caused by cardiac dysfunction and is characterized by left 
ventricular hypertrophy or dilatation due to, among other things pressure overload 
(hypertension). Hypertension is the number one regulating risk factor for the development of 
heart failure in developing countries. Although, heart failure accounts for a substantial 
proportion of morbidity and mortality in both men and women, studies have shown that men 
are at a higher risk of developing heart failure than women. However, the efforts to 
understand gender influences on the risks of cardiovascular disease in the context of 
hypertension have not been well established. A leading cause of heart failure in South Africa 
is hypertension. It is crucial to understand the impact of gender on the development of heart 
failure in the settings of hypertension.  
The progression to heart failure in systemic hypertension is associated with the initial 
development of left ventricular hypertrophy, said to be a compensatory mechanism. It is 
suggested that the compensated hypertensive hypertrophy could be as a consequence of 
sympathetic nervous system (SNS) activation. Indeed, previous studies from our laboratory 
have studied the impacts of excessive SNS activation on cardiovascular changes, using the 
beta adrenergic receptor agonist, daily (isoproterenol, ISO). In this regard, these studies 
revealed that SNS activation causes compensatory ventricular hypertrophy to cardiac 
dilatation. In addition, previous studies have reported gender-related differences in SNS 
activation (with reduced activation in females). Hence it is possible that gender difference in 
progression to heart failure may be explained by differential responses to beta-adrenergic 
activation in the context of hypertension. 
xvii 
 
My study therefore aimed to investigate the impact of gender on beta-adrenergic 
receptor stimulation in the setting of hypertensive animal model. The aims, objectives and 
justification for this study are further included in chapter one of the introduction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter One - Introduction 
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1. Introduction 
Heart failure (HF) is a common cause of cardiovascular disease worldwide (Regitz-
Zagrosek & Seeland, 2011) including in South Africa (Stewart et al. 2008). Similar to what has 
been reported on in other communities of African descent (Akinkugbe et al. 1991), the major 
risk factor for congestive heart failure is hypertension in urban, economically developing 
communities of black African ancestry in South Africa (Stewart et al. 2008). There is no 
question that the main challenge in this regard is the lack of access to adequate health care in 
these communities where a large proportion of individuals with hypertension go undetected or 
untreated (Steyn et al. 2001). Furthermore, when treated for hypertension only few 
hypertensives from these communities achieve target blood pressures (Steyn et al. 2001), 
highlighting the importance of specific anti-hypertensive treatment for black African ancestry. 
In the progression from hypertension to heart failure it is now acknowledged that there 
are factors other than blood pressure which predict this transition process. Identifying and 
targeting these changes in patients with hypertension is a critical issue. Animal and human 
studies have provided significant evidence to suggest that males and females respond 
differently to cardiovascular diseases (Adams et al. 1999, Halm et al. 2000, Hayward et al. 
2000, Dubey et al. 2002, & Rossouw et al. 2002). In epidemiologic studies, women with 
congestive heart failure appear to have better survival rates than men with congestive heart 
failure (Schocken et al. 1992, Ho et al. 1993, & Adams et al. 1999). In the Framingham Heart 
Study, once heart failure is present, the median survival time was noted to be 3.2 years for 
women and only 1.7 years for men (Ho et al. 1993). In the NHANES-I study; the 1-year 
mortality rate was 23.8% for women with heart failure and 54.4% for men with heart failure 
(Schocken et al. 1992). Data from the FIRST study showed that higher survival rates for 
women were evident in the case of non-ischaemic as opposed to ischaemic causes of heart 
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failure (Adams et al. 1999). In South Africa, men with heart failure from urban, developing 
communities are more likely to have impaired systolic function than women with heart failure, 
although women present with more overt symptoms of heart failure (Stewart et al. 2008).  
Despite numerous studies implicating gender as a possible factor in mediating the 
progression to heart failure, studies on the effects of gender on the progression to heart failure 
in the presence of hypertension (pressure overload) are limited. Moreover, as neurohumoral 
activation, particularly the sympathetic nervous system (SNS) plays a key role in hypertension 
and the progression to heart failure, the impact of gender on SNS-induced heart failure remains 
to be elucidated. Hence the aim of my study was to determine the impact of gender on β-
adrenergic-induced cardiac dilatation and dysfunction. As a background to this aim, in chapter 
one, I will first discuss cardiac hypertrophy, cardiac dilatation and cardiac dysfunction. I will 
then discuss the effects of gender on cardiac hypertrophy and the progression to heart failure; 
the role of the sympathetic nervous system in the progression to heart failure; the impact of 
gender on sympathetic nervous system activation; and then finally, the impact of gender on 
sympathetic nervous system-induced progression to heart failure. 
 
1.1 Cardiac hypertrophy 
The progression to heart failure in pressure overload states such as systemic hypertension 
is characterized by the initial development of concentric left ventricular hypertrophy, which is 
an increase in the ratio of wall thickness to chamber dimension (Grossman et al. 1975, 
Swynghedauw et al. 1999, Hein et al. 2003, & Opie et al. 2006). Left ventricular hypertrophy 
is a physiological compensatory response to adapt to increased stress or tension on the walls of 
the heart. This physiological adaptation is according to La Place’s law [wall tension = (systolic 
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pressure x chamber radius)/ 2 (wall thickness)] (Grossman et al. 1975, & Laskey et al. 1984). 
This adaptive response is characterized by the parallel replication of contractile units 
(sarcomere) in cardiomyocytes, which increases the cardiomyocyte width (Grossman et al. 
1975). The increase in the left ventricular wall thickness normalizes systolic left ventricular 
wall stress in order to maintain pump function (ejection fraction and cardiac output) (Grossman 
et al. 1975). The development of concentric ventricular hypertrophy is an early milestone 
during the clinical development of heart failure and as such it is an important independent risk 
factor for cardiac mortality and morbidity (Levy et al 1990, & Hunter and Chien 1999).  
There are two types of cardiac hypertrophy, namely concentric hypertrophy – caused 
primarily by chronic left ventricular (LV) pressure overload; and also eccentric hypertrophy – 
caused primarily by chronic LV volume overload (Grossman et al. 1975, & Ganau et al. 1992). 
As discussed above concentric hypertrophy is characterized by wall thickening in order to 
resist increased systolic wall stress due to pressure overload and thus acting as feedback 
inhibition. As the wall thickens by parallel replication of sarcomeres (figure 1.1), concentric 
hypertrophy may reduce cardiac filling because of a reduced radius (Grossman et al. 1975, & 
Norton et al. 1993). Hence the diastolic pressure-volume curve would be left shifted compared 
to normal, and the volume at a pressure of 0 mm Hg (V0) would be decreased (figure 1.1). 
Concentric hypertrophy is therefore characterized by an increased wall thickness to radius 
ratio.  
With respect to eccentric hypertrophy, in response to volume overload induced increases 
in end diastolic wall stress the chamber enlarges due to a series replication of sarcomeres 
(figure 1.1).  
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Figure 1.1: Diagrammatic representation of changes in the left ventricular end diastolic 
pressure-volume relationship in cardiac hypertrophy. The normal diastolic pressure-
volume relationship is indicated by the solid line; a left shift in the pressure-volume 
relationship with decreased volume at which left ventricular (LV) end diastolic pressure 
equals zero (V0) and increased wall thickness to radius ratio as occurs in concentric 
hypertrophy is indicated by the dotted line; and a right shift in the pressure-volume 
relationship with an increased V0 but normal wall thickness to radius ratio as occurs in 
eccentric hypertrophy is indicated by the dashed line 
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According to the law of La Place, the enlarged chamber leads acutely to an increased peak 
systolic wall stress, which then causes wall thickening of a sufficient magnitude to resist 
systolic stress (Grossman et al. 1975, & Laskey et al. 1984). It should then be noted that 
chamber enlargement together with wall thickening results in comparable ratios of wall 
thickness to chamber dimensions as that of a normal ventricle (figure 1.1). However, 
ventricular eccentric hypertrophy shifts the diastolic pressure-volume curve to the right and V0 
is increased. 
Although both concentric and eccentric hypertrophy are adaptive processes that occur in 
response to increased loading conditions (pressure or volume respectively), in order to reduce 
wall stress back to normal levels, these processes are not limitless. Moreover they are 
associated with the activation of neurohumoral pathways which have detrimental effects on the 
heart. Hence cardiac hypertrophy although initially a compensatory response may become 
maladaptive. Maladaptive hypertrophy occurs when the ventricle enlarges; the ventricular wall 
becomes thinner and consequently the wall thickness to radius ratio decreases (Swynghedauw 
et al. 1999, Janicki et al. 2004, & Opie et al. 2006). In the next section I will therefore discuss 
the processes by which compensatory hypertrophy progresses to maladaptive (LV dilatation). 
 
1.2 Cardiac dilatation 
As described above, cardiac dilatation is a maladaptive process characterised by chamber 
enlargement and wall thinning. The presence of ventricular dilatation can be detected in vivo 
using echocardiography. Alternatively, ex vivo assessments can be made using an isolated 
perfused heart system. The details of these two methods (in vivo and ex vivo) will be discussed 
thoroughly under the methods section (see chapter 2). However, it is important to discuss the 
relative accuracy of these two methods in determining the presence of LV dilatation. 
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In this regard in vivo assessments are confounded by the impact of heart rate and loading 
conditions. Indeed, increases in volume load would result in increased filling volumes and 
therefore enlarged chamber dimensions. Hence, an increased left ventricular end diastolic 
diameter (LV EDD) would be measured on echocardiography. Alternatively, increases in 
pressure load could result in decreases in stroke volume and hence enlarged chamber 
dimensions. Furthermore, increases in heart rate could similarly result in enlarged chamber 
dimensions as a consequence of reductions in stroke volume. In comparison the isolated 
perfused heart system allows for load and heart rate independent measures. Firstly, the hearts 
are paced at a fixed rate and secondly pressures are recorded at stepwise increments in volume. 
As the heart is isolated from the body, there are also no external neurohumoral influences. 
Therefore LV dilatation is defined as a right shift in the diastolic pressure-volume curve 
obtained from an isolated perfused heart system (Gibbs et al. 2004, & Gilbert and Glantz 1989) 
(figure 1.2). 
Our group have studied factors which contribute to the transition from cardiac 
hypertrophy to cardiac dilatation, including neurohumoral activation (Badenhorst et al. 2003a, 
Gibbs et al. 2004, Veliotes et al. 2005, & Osadchii et al. 2007). These studies showed that 
sympathetic nervous system activation plays a key role (Woodwiss et al. 2001, Badenhorst et 
al. 2003a, Gibbs et al. 2004, & Veliotes et al. 2005). In addition, increased activity of the 
renin-angiotensin-aldosterone system has been shown to mediate cardiac dilatation (Veliotes et 
al. 2005). Indeed, aldosterone receptor blockade prevents the progression from compensatory 
cardiac hypertrophy to cardiac dilatation. Increased sympathetic nervous system activity is 
associated with alterations in the characteristics of cardiac collagen (Woodiwiss et al. 2001, & 
Badenhorst et al. 2003a).  
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Figure 1.2: Example of the left ventricular end diastolic pressure-volume relationship 
The normal diastolic pressure-volume relationship is indicated by the solid line, and a right 
shift in the pressure-volume relationship, indicative of cardiac dilatation, is indicated by the 
dashed line. The volume intercept [volume at which left ventricular (LV) end diastolic pressure 
equals zero (V0)] is increased in the right shifted relationship. 
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Although synthesis of cardiac collagen is increased with sympathetic nervous system 
activation, the new collagen has reduced cross-links (Woodiwiss et al. 2001, & Badenhorst et 
al. 2003a). Consequently the tethering of cardiomyocytes is reduced. This results in side-to-
side slippage of the cardiomyocytes and ultimately dilatation. In addition, cardiomyocyte death 
by either apoptosis or necrosis is also believed to play a role (Yussman et al. 2002). 
Subsequent to cardiomyocyte death, side-to-side slippage has also been shown to occur and 
hence dilatation (Yussman et al. 2002).   
The presence of LV dilatation is not benign; it is indeed a maladaptive process which 
impacts on cardiac function (Janicki et al. 2004). In particular, pump (chamber) function, either 
in the presence or the absence of myocardial dysfunction, is impaired. In the next section I will 
therefore discuss measurements of cardiac function and the impacts of LV dilatation on cardiac 
function. 
 
1.3 Cardiac function and the impacts of cardiac dilatation  
Cardiac function includes both diastolic function (capacity of the heart to fill with blood 
during diastole) and systolic function (capacity of the heart to eject blood during systole). I will 
focus my discussion on systolic cardiac function as this is most relevant to the impacts of 
cardiac dilatation. Although cardiac function can be assessed in vivo using echocardiography, 
as discussed in section 1.2 above, these measurements are influenced by heart rate and loading 
conditions. Hence, ex vivo assessments are required to assess cardiac function in the absence of 
the influences of heart rate, loading conditions and neurohumoral activity. Using isolated 
perfused heart systems, pressure and volume are recorded. Systolic cardiac chamber function is 
assessed from the slope of the linear portion of the developed (systolic minus diastolic) 
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pressure-volume relationship (Ees) (figure 1.3). Intrinsic systolic myocardial function is 
assessed from the slope of the systolic stress-strain relationship (En), where stress is calculated 
from left ventricular systolic stress = 1.36 x LV developed pressure x (LVV)
2/3 
/ [LVV + (0943 
x LV mass)]
2/3
 – LVV2/3 (Norton et al. 2002, Badenhorst et al. 2003b, & Veliotes et al. 2005) 
(figure 1.3). 
As cardiac dilatation is known to be a precursor of pump dysfunction and clinical heart 
failure (Pfeffer et al. 1992, Gaudron et al. 1993, Vasan et al. 1997), the question arises as to 
how cardiac dilatation results in reduced pump function? As cardiac dilatation is associated 
with a reduced relative wall thickness, according to La Place’s Law, wall tension or stress will 
be increased. An increase in wall stress will result in an increase in myocardial oxygen 
consumption; hence the myocardial oxygen demand-to-supply ratio may be increased in 
cardiac dilatation. An increase in myocardial oxygen demand-to-supply ratio may subsequently 
lead to a reduction in myocardial contractility. Alternatively, cardiac chamber function may be 
reduced in the absence of alterations in myocardial contractility (Norton et al. 2002). It is 
possible that in a dilated ventricle, inappropriate force transduction occurs during the 
contraction of cardiomyocytes, which would result in pump dysfunction (Sallin 1969). In 
addition, in a dilated ventricle larger chamber volumes may be required to produce 
cardiomyocyte stretch in order to recruit the Frank-Starling effect. Indeed, when the structure 
of the ventricle changes the mechanics of systolic function are affected which results in a low 
cardiac output (Laskey et al. 1984, & Cohn et al. 2000). 
Having discussed left ventricular hypertrophy, cardiac dilatation and the progression to 
systolic dysfunction, I will now discuss the literature on the effects of gender on left 
ventricular hypertrophy and the progression to heart failure. 
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Figure 1.3: Diagrammatic representation of changes in the slope of the developed 
pressure-volume relationship (upper panel) and the stress-strain relationship (lower 
panel). A decreased slope of the developed pressure-volume relationship (Ees) indicates 
decreased systolic chamber function, and a decreased slope of the stress-strain relationship 
(En) indicates decreased systolic myocardial function. 
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1.4 Gender effects on left ventricular hypertrophy and the progression to heart failure  
Gender has been shown to quantitatively and qualitatively influence the characteristics of 
left ventricular hypertrophy (LVH), as well as progressive heart failure (HF) (Topol et al. 
1985, Carrol et al. 1992, & Aurigemma et al. 1994). The observational Studies of Left 
Ventricular Dysfunction (SOLVD) patient registry reported a higher annual risk for heart 
failure-related mortality in women (Bourassa et al. 1993); however several studies have 
suggested that women with HF have better survival rates than men (McKee et al. 1971, 
Schocken et al. 1992, Ho et al. 1993, & Adams et al. 1999). The apparent controversial data in 
the SOLVD study may be due to higher age or other confounding factors in women. In 652 
members of the Framingham Study the median survival after the onset of heart failure was 1.7 
years in men and 3.2 years in women (Ho et al. 1993). Possible explanations for the gender 
differences in HF survival include myocardial adaptation to pressure overload (Schaible et al. 
1984, Buttrick et al. 1993, Witt et al. 2008, & Fliegner et al. 2010). In this regard, human 
studies have reported that hypertensive women develop a more marked concentric hypertrophy 
and higher indices of systolic function than men (Carrol et al. 1992, Aurigemma et al. 1994). 
Indeed, the preponderance of extreme hypertensive hypertrophy with a subnormal wall stress 
resulting in a supernormal pump or ejection performance is higher in elderly black women than 
men (Topol et al. 1985, & Douglas et al. 1995). However, these findings may be because men 
with extensive hypertrophy have succumbed to the complications of cardiovascular disease at 
an earlier age. Nevertheless, in autopsies, apoptosis and necrosis of cardiomyocytes are less 
evident in the failed hearts of women than in those belonging to men (Guerra et al. 1999, & 
Olivetti et al. 1997). These findings suggest that the female gender may be protected against 
cardiac damage and dysfunction.  
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Animal studies have provided similar evidence to human studies. Indeed, animal studies 
have shown the effects of gender on cardiac changes, not only with load and heart rate 
dependent echocardiographic measurements obtained in vivo; but importantly with load and 
heart rate-independent measures of cardiac dilatation and pump dysfunction ex vivo under 
controlled conditions. A summary of the most pertinent animal studies assessing the effects of 
gender on LVH and the progression to heart failure is provided in table 1.1. Most of these 
studies used in vivo assessments of cardiac remodelling in response to either pressure (Pfeffer 
et al. 1982, Douglas et al. 1998, & Tamura et al. 1999) or volume (Brower et al. 2003, 
Skavdahl et al. 2005, Dent et al. 2010, & Dent et al. 2012) overload. In addition, two of the 
studies assessed cardiac dimensions in vivo in a genetically hypertensive model; namely the 
Spontaneous Hypertensive Rat (SHR) (Pfeffer et al. 1982, & Tamura et al.1999). Hence the 
data from these studies need to be interpreted with caution as the results may be confounded by 
differences in loading conditions or heart rate. However, other studies used both in vivo and ex 
vivo (Gardener et al. 2002, Weinberg et al. 1999, & Chan et al. 20110 or ex vivo (Jain et al. 
2002, & Monasky et al. 2008) assessments of cardiac dimensions and function in either 
pressure (Weinberg et al. 1999, & Chan et al. 2011) or volume (Gardner et al. 2002) overload 
conditions. Compared to in vivo assessments ex vivo assessments of cardiac dimensions and 
function are a more reliable technique, because they allow for the exclusion of the influences 
of loading conditions and heart rate as discussed in section 1.2 above.  
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Table 1.1: Summary of animal studies reporting on the effects of gender on the progression from left ventricular hypertrophy to heart 
failure.  
Author  Model  Animal strain In vivo/ 
Ex vivo  
Findings & Conclusion  
Pfeffer et al. 1982 Pressure overload 
(hypertension) 
Spontaneously 
Hypertensive Rats 
(SHRs) 
In vivo Female SHR had normal heart dimensions and function; male SHR had LV 
dilatation & LV dysfunction and HF. 
Douglas et al.1998 Pressure overload 
induced by aortic 
banding 
Wistar rats In vivo Female rats were protected from chamber dilatation and sustained concentric 
hypertrophy compared to male rats. 
Tamura et al. 1999 Pressure overload 
(hypertension) 
Spontaneously 
Hypertensive Rats 
(SHRs) 
In vivo Hypertrophy was present from 2, 4 and 6 months in both genders. At 18 
months, males had a cardiac dilatation, whereas females only had it at 24 
months. Therefore, reduced adaptive hypertrophic reserve was observed in 
males. 
Weinberg et al. 1999 Pressure overload 
induced by aortic 
banding (stenosis) 
Wistar rats In vivo & 
Ex vivo 
 
In contrast to females, males showed a reduced contractility after 6 weeks of 
pressure overload, but the patterns of LVH & systolic wall stress were similar in 
both genders. Hence males adapt differently to pressure overload despite a 
similar LVH and systolic wall stress to females. 
Gardner et al. 2002 Volume overload, 
Arteriovenous (AV) 
fistula 
Sprague-Dawley 
(SD) rats 
In vivo & 
Ex vivo 
Male rats had LV dilatation and increased compliance compared to female rats. 
Hence female rats adapt more favourably to volume overload than male rats. 
Jain et al. 2002 Pressure overload 
after myocardial 
Dahl salt-
sensitive (DS) 
Ex vivo Females developed LV concentric hypertrophy with no dilatation, whereas 
males had LV eccentric hypertrophy and dilatation. Females responded more 
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infarction (MI) rats favourably to the hemodynamic overload after large MI. 
Gao et al. 2003  Over-expression of 
β-adrenergic 
receptors 
Transgenic (TG) 
mice 
In vivo  Male mice had LV dilatation & pump dysfunction compared to female mice, 
Therefore, there was greater survival in female transgenic mice compared to 
male mice. The LV dilatation and pump dysfunction in the male mice was 
improved with castration. 
Brower et al. 2003 Volume overload, 
Arteriovenous (AV) 
fistula 
Sprague-Dawley 
(SD) rats 
In vivo Compared to male rats there was reduced heart failure in female rats which was 
associated with preserved LV function and chamber size. 
Skavdahl et al. 2005 Pressure overload, 
aortic banding 
 
β-estrogen 
receptor knockout 
(β-ERKO) & 
wild-type (WT) 
mice 
In vivo WT male mice developed hypertrophy when subjected to TAC, also sham 
females had hypertrophy after TAC. Therefore, oestrogen receptor-β plays an 
important role in attenuating the hypertrophic response to pressure overload. 
Monasky et al. 2008 Pressure overload, 
Isoproterenol (ISO) 
 Lewis-Brown 
Norway F1 
(LBN F1) rats  
Ex vivo 
 
Basic mechanical performance of healthy isolated myocardium under 
physiological conditions is not different between males and females, and a 
different response to stress must underlie gender-based differences in cardiac 
performance. 
Dent et al. 2010 Volume overload, 
Arteriovenous (AV) 
shunt. 
Sprague-Dawley 
(SD) rats 
In vivo Male rats in contrast to female rats showed increased LV dimensions and 
reduced pump function. Gender differences in cardiac function may be due to 
differences in the type of cardiac remodelling as a consequence of AV shunt. 
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Chan et al. 2011 Pressure overload 
(hypertension) 
Spontaneously 
Hypertensive Rats 
(SHRs) 
In vivo & 
Ex vivo 
At 15 months of age, SHR males develop LV dilatation, systolic & diastolic 
dysfunction, but not females. Therefore, ageing male SHRs in contrast to 
female SHRs are more susceptible to heart failure.  
Dent et al. 2012 Volume overload, 
Arteriovenous (AV) 
shunt. 
Sprague-Dawley 
(SD) rats 
In vivo β-AR mechanism is downregulated in males and upregulated in females. 
Therefore, oestrogen is responsible for the upregulation of β-AR mechanism 
and maintenance of cardiac function in females exposed to volume overload. 
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With respect to LVH, most authors reported that females develop concentric hypertrophy 
and males develop eccentric hypertrophy in response to either pressure (Douglas et al. 1998, 
Tamura et al. 1999, & Jain et al. 2002) or volume overloads (Gardner et al. 2002). 
Hypertensive female rats were noted to have a greater capacity for hypertrophy compared to 
hypertensive male rats (Tamura et al. 1999). Indeed, Pfeffer et al. (1982) and Chan et al. 
(2011) reported that LV dilatation occurred in male spontaneously hypertensive rats (SHR) but 
not in female SHR. These findings are in line with the fact that healthy male rats have larger 
cardiomyocytes than female rats presumably because of the increased volume load from a 
larger body mass (Bai et al. 1999). Moreover, in transgenic mice with over-expression of β-
adrenergic receptors, Gao et al. (2003) reported from in vivo assessment that LV dilatation 
occured in male but not female mice. Furthermore, in a review by Du (2004) it was suggested 
that male mice are more sensitive than their female counterparts to genetic interventions 
leading to pathologic hypertrophy and HF. 
In addition to gender effects on LV dimensions, previous studies have reported on gender 
differences in LV function. In response to pressure (Pfeffer et al. 1982, Weinberg et al. 1999, 
& Chan et al. 2011) or volume (Gardner et al. 2002, Brower et al 2003, & Dent et al. 2010) 
overload, male rats developed systolic dysfunction and were more susceptible to HF in 
comparison to female rats. Monasky et al. (2008) demonstrated that both male and female rats 
have the same LV function under normal physiological conditions, but LV function was 
reduced in males under pressure overload. In addition, in response to β-adrenergic receptor 
over-expression male mice developed pump dysfunction and had reduced survival compared to 
female mice (Gao et al. 2003). Importantly in the latter study (Gao et al. 2003), the LV 
dilatation and pump dysfunction in the male mice was improved with castration. In addition, 
Dent et al. (2012) reported that β-adrenergic receptor upregulation occurred in female rats 
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which maintained cardiac function when exposed to volume overload. These authors claimed 
that oestrogen was responsible for the β-adrenergic receptor upregulation. Therefore, the 
observed sex differences in table 1.1 support the hypothesis that sex hormones are involved in 
protecting females against either pressure or volume overload induced progression to HF. 
However, the mechanisms by which this occurs are currently unclear.  
Both oestradiol and testosterone have been proposed as candidates that may explain the 
gender-related differences in left ventricular remodelling and heart failure outcomes (Marsh et 
al. 1998, Mendelsohn et al. 1999, Gao et al 2003, Hodson et al. 2014). With respect to the 
potential role of testosterone in heart failure, testosterone has been shown to elicit hypertrophy 
of cardiomyocytes both in vitro and in vivo (Marsh et al. 1998, & Cabral et al. 1988). 
However, in contrast to what would be predicted, low circulating testosterone concentrations 
are a marker of a poor prognosis for the survival of men suffering from cardiac failure 
(Jankowska et al. 2006).
 
Moreover, in men with chronic heart failure, testosterone-replacement 
therapy improves cardiac output as well as the symptoms of heart failure (Pugh et al. 2003), 
suggesting a protective effect of normal levels of testosterone. Recent findings from our 
laboratory nevertheless show that castration does not influence the extent of LV dilatation 
induced by chronic adrenergic activation (Hodson et al. 2014). Clearly the role of testosterone 
in the process of progression to heart failure is controversial. 
With respect to the potential role of oestrogen in heart failure, oestrogen-replacement 
therapy given to postmenopausal women is associated with a better prognosis in hypertrophic 
cardiomyopathy, as well as a lower incidence of heart failure
 
after a myocardial infarction 
(Reis et al. 2000, Shlipak et al. 2001, & Lindelfeld et al. 2003). In rodent models of cardiac 
pathology, oestrogen reduces myocardial hypertrophy induced by pressure or volume overload 
(Cabral et al. 1988, Malhotral et al. 1990, Weinberg et al. 1999, Sharkey et al. 1999, Gardner et 
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al. 2010). Skavdahl et al. (2005) have shown that β-oestrogen receptors are responsible for 
reducing the hypertrophic response to pressure overload in female rats. Oestrogen 
administration in ovariectomized female rats under volume overload prevents the degradation 
of collagen associated with matrix metalloproteinase (MMP) activation (Brower et al. 2002, 
Chancey et al. 2005 & Janicki et al. 2006). In addition, gender-related differences have also 
been observed in the activation of the mitogen-activated protein kinase (MAPK) pathway in 
compensated hypertrophy (Dash et al. 2003). As oestrogen decreases the activation of p38 
MAPK (Angele et al. 2003, & Dash et al. 2003), the gender-specific regulation of p38 MAPK 
may be in part, responsible for the gender differences in the hypertrophic response following 
pathological conditions. In addition, oestrogen administration may prevent cardiomyocyte 
apoptosis and the development of pump dysfunction in pressure overload states (Dubey et al. 
1998, Satoh et al. 2007, & Mahmoodzadeh et al. 2010). In vitro and in vivo studies have 
identified oestrogen as a potential inhibitor of cardiomyocyte apoptosis (Pattern et al. 2004, 
Satoh et al. 2007, & Fliegner et al. 2010), fibrosis and MMP activity (Dubey et al. 1998, & 
Mahmoodzadeh et al. 2010), as well as RAAS activity (Holycross et al. 1997, Schunkert et al. 
1997, & Malkin et al. 2006).  
The ability of gender and sex hormones to modify a number of the processes that may 
explain the progression from compensated hypertensive hypertrophy to HF raises the question 
as to whether there is a role for gender in the transition to HF. In this regard, activation of the 
sympathetic nervous system may be a key process in the transition to heart failure in 
hypertension. Hence before discussing the potential impact of gender on sympathetic nervous 
system-induced adverse effects on the heart, the role of the sympathetic nervous system in 
LVH and the progression to HF will be discussed. 
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1.5 Role of sympathetic nervous system activation in the progression to heart failure 
A strong association has been demonstrated between sympathetic nervous activation and 
the failing heart (Kaye et al. 1996, Pepper et al. 1999, & Brunner-La Rocca et al. 2001). 
Activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone 
system (RAAS) is known to occur in response to increases in cardiac wall stress. Furthermore, 
continual cardiac wall stress would favour more sympathetic overactivity which has major 
adverse effects on cardiac remodelling (Brunner-La Rocca et al. 2001, Badenhorst et al. 2003a, 
& Veliotes et al. 2005). Indeed, a potential role of sympathetic nervous system activation in the 
progression to heart failure from hypertrophy is well documented (Anderson et al. 1989, Kaye 
et al. 1996, Pepper et al. 1999, Brunner-La Rocca et al. 2001, Badenhorst et al. 2003, Veliotes 
et al. 2005, Floras 2009, Triposkiadis et al. 2009, & DiBona et al. 2013). Studies have shown 
that sympathetic nervous system overactivation may contribute toward the transition to heart 
failure in LVH (Brunner-La Rocca et al. 2001, Badenhorst et al. 2003, Schlaich et al. 2003, & 
DiBona et al. 2013). In addition, in pressure overload induced ventricular hypertrophy an 
increased myocardial norepinephrine (NE) concentration has been measured in the coronary 
sinus (Agabiti-Rosei et al. 1987, Kelm et al. 1996, & Brunner-La Rocca et al. 2001). Similarly, 
in our laboratory, we have demonstrated that hypertensive rats with compensatory 
hypertrophy, when exposed to pressure overload conditions, produced increased myocardial 
NE concentrations in the coronary effluent (Veliotes et al. 2005). Moreover, transgenic animals 
with decreased adrenergic activation are protected against the development of HF when 
exposed to pressure overload conditions (Esposito et al 2002). In this regard, it has been shown 
that excessive sympathetic nervous system (SNS) activation down-regulates beta-adrenergic 
receptor (β-AR) mediated signal transduction which may ultimately result in depressed cardiac 
function (Böhm et al. 1995, Dhalla et al. 1997, & Osadchii et al. 2007). Finally, in our 
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laboratory we have further demonstrated that hypertensive animals with compensated 
hypertrophy are susceptible to chronic β-AR activation and consequently develop cardiac 
dilatation and pump dysfunction (Woodiwiss et al. 2001, Tsotetsi et al. 2001, Badenhorst et al. 
2003, & Veliotes et al. 2005). 
 Importantly, the pathophysiological mechanism for this transition to HF from LVH in 
sustained (chronic) β-AR activation is explained by the increased NE concentrations that 
ultimately result in an increased inotropic response of the cardiomyocytes through post 
receptor activation of adenylate cyclase (AC), an increase in the intracellular concentrations of 
the second messenger cyclic adenosine monophosphate (cAMP) and subsequently myocardial 
contractility (Dhalla et al. 1997, & Dent et al. 2010). This signalling cascade leads to 
compensatory hypertrophy and subsequently dilatation. Among other pathways, in vitro and in 
vivo studies have shown that the mitogen-activated protein kinases (MAPK) are important 
switches in pathways that promote the transition to LV dilatation from hypertrophy (Sheng et 
al. 1997, Wang et al. 1998, Hunter et al. 1999, & Dash et al. 2003). For instance, in mice p38 
mitogen-activated protein kinases are strongly activated by pressure overload which is usually 
accompanied by an increase in the rate of cardiomyocyte death (apoptosis) (Wang et al. 1998). 
Indeed, adrenergic activation promotes cardiomyocyte apoptosis through activation of β1-
adrenergic receptor cAMP-dependent protein kinase A and mitogen-activated protein kinase 
(MAPK) pathways (Singh et al. 2001) and indirectly through RAAS stimulation (De Angelis et 
al. 2002). Apoptosis or necrosis may reduce the capacity to tether cardiomyocytes and hence 
promote side-to-side slippage and consequently cardiac dilatation (Beltrami et al. 1995). 
Importantly, Chan et al. 2004 reported that the transition from cardiac hypertrophy to heart 
failure in hypertension may be prevented by the blockade of β-AR independent of blood 
pressure effects. 
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These data clearly show that excessive adrenergic activation is a crucial process in the 
transition from LV dilatation to HF in hypertension. However, it is unclear whether there are 
alternative blood pressure independent effects that may explain the transition to heart failure in 
hypertension. Importantly, the effects of gender on LVH and progression to HF (as discussed 
in section 1.4 above) suggest that gender may be one such alternative blood pressure 
independent effect. As SNS activation plays a key role in the transition from LVH to HF as 
discussed what evidence is there of gender effects on SNS activation?  
 
1.6 Gender effects on sympathetic nervous system activation 
It is known that gender differences exist in the regulation of the SNS. In healthy men and 
women at rest, the blood pressure (BP) is similar but heart rate (HR) tends to be higher in 
women (Hinojosa-Laborde et al. 1999). However, human studies have shown that 
measurements of SNS activity are reduced in healthy women compared to healthy men (Ng et 
al. 1993, & Jones et al. 1996). This presents a question: what is the mechanism underlying this 
increase in HR, in the presence of a decreased SNS activity in healthy women?  
The differences in the development of hypertension in males and females are strongly 
associated with gender differences in the regulation of SNS activity (Hogarth et al. 2007, 
Lambert et al. 2007, & Coulson and Cockcroft 2011). Hypertension in women is associated 
with a lower level of sympathetic hyperactivity than in men (Hogarth et al. 2007). Gender 
differences have been demonstrated in the regulation of the SNS through the involvement of 
the beta-adrenergic system (Kneal et al. 2000, Hart et al. 2009, & Hogarth et al. 2011). 
Increased β2-AR sensitivity offsets α-adrenergic mediated vasoconstriction in pre-menopausal 
women (Kneal et al. 2000). Whereas men have an increased SNS activity due to β-adrenergic 
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activation which ultimately results in reductions in coronary blood flow velocity in comparison 
to women (Momen et al. 2010). Furthermore, several human studies have evaluated gender 
differences in baroreflex regulation of cardiac SNS activity (Abdel-Rahman et al. 1994, & 
Desai et al. 1997). These studies have shown that the reflex bradycardia in response to 
increases in BP is diminished in women compared to in men. There is increasing evidence to 
show the existence of gender-related differences in sympathetic activation and baroreflex 
control of autonomic function (Yamasaki et al. 1996, Umetani et al. 1998, & Aroson et al. 
2000). Disturbances in baroreflex activation are characterized by profound abnormalities in 
autonomic control; whereby there is sympathetic overactivity (Cohn et al. 1984, & Floras and 
Pitt et al. 1993) and parasympathetic withdrawal (Binkley et al. 1991, & Floras et al. 1993).  
To my knowledge, there are no animal data available to show that bradycardia is 
different in males and females. However, with respect to gender differences in reflex 
tachycardia in response to a decrease in BP, there is conflicting evidence. One study has shown 
that female rats respond with increases in HR in response to low BP (Buñag et al. 1975). 
Whereas, another study reported that there are no gender differences in reflex-mediated 
tachycardia (Crofton et al. 1988). Several animal studies have used the mediators of the β-AR 
signalling pathway to show gender differences in SNS activation; including catecholamines, β-
AR density and affinity, Ca
2+
 current density, cAMP, AC activity, and MAPK activation 
(Schwertz et al. 1999, Vizgirda et al. 2002, Dash et al. 2003, Dent et al. 2010, McIntosh et al. 
2011, Dent et al. 2012). In these studies it has been shown that male rats have more β-AR and 
greater cAMP production, which indicates that males have an enhanced response to β-
adrenergic stimulation (Schwertz et al. 1999, & Vizgirda et al. 2002). Transgenic male mice 
with phospholamban (PLB) over-expression exhibit contractile dysfunction and hypertrophy 
due to early p38 MAPK activation which promotes compensatory hypertrophy. Whereas 
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transgenic female mice show a temporal delay in p38 MAPK activation despite contractile 
dysfunction (Dash et al. 2003). This may be attributed to oestrogen which modulates MAP 
kinase phosphatase-1 (MKP-1) expression and thus inhibits MAPK activation (Nuedling et al. 
1999).  
Having summarized the data indicating that there are indeed gender differences in SNS 
activation and that SNS activation plays a key role in the transition from LVH to HF, the 
question then arises as to whether gender impacts on SNS-induced progression to HF. 
 
1.7 Gender effects on sympathetic nervous system induced progression to heart failure 
As discussed in the previous section, disturbances in baroreflex activation may result in 
abnormalities in autonomic control and subsequently sympathetic overactivity (Cohn et al. 
1984, & Floras et al. 1993) as well as parasympathetic withdrawal (Binkley et al. 1991, & 
Floras et al. 1993). A method that measures noninvasive heart rate variability (HRV) has 
been largely used to explain the relationship between sympathetic and parasympathetic 
nervous system function in modulating heart rate (Mortara et al. 1994, Butler et al. 1997, 
Poniskowski et al. 1997, & Jiang et al. 1997). Using an analysis of heart rate variability 
(HRV) it is possible to study the sympathetic over-activation (Cohn et al. 1984, & Floras et 
al. 1993) as well as parasympathetic withdrawal (Binkley et al. 1991, & Floras et al. 1993). 
Among other indexes of HRV, high frequency heart rate fluctuations are associated with 
healthy cardiac function (Hyndman et al. 1971, Billman et al. 1990, Ryan et al. 1994); 
whereas, low beat to beat HRV is associated with heart failure (Saul et al. 1988, & Casolo et 
al. 1991). Indeed, gender-related differences of the HRV as an index of autonomic system 
function for normal subjects have been reported in several studies (Cowan et al. 1994, Ryan 
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et al. 1994, Huikuri et al. 1996, Ramaekers et al. 1998, & Umetani et al. 1998). A few of 
these studies reported an augmented parasympathetic activity as determined by a higher HRV 
in healthy women compared with healthy men (Ryan et al. 1994, & Huikuri et al. 1996). In 
contrast, other studies have shown a significantly lower HRV in healthy female subjects 
compared to healthy male subjects (Cowan et al. 1994, Ramaekers et al. 1998, & Umetani et 
al. 1998). Moreover, some studies reported similar HRV between men and women (Bigger et 
al. 1995, & Liao et al. 1995). Importantly, there is only one study that reported gender-related 
differences in HRV in patients with heart failure (Aroson et al. 2000) (table 1.2). This study 
reported that women with heart failure have a higher HRV compared to men with heart 
failure. Therefore, suggesting that women with heart failure have an attenuated sympathetic 
activation and augmented parasympathetic activity compared with men. 
Other techniques used to assess sympathetic over-activity in human studies include 
increases in plasma norepinephrine (NE), central sympathetic outflow, and NE spillover from 
activated sympathetic nerve fibers (Pepper et al. 1999, Triposkiadis et al. 2009, & Mitoff et 
al. 2011). These techniques are reliable and are considered to best quantify cardiac SNS 
activity, particular in CHF patients (Hasking et al. 1986, Kaye et al. 1995, Newton et al. 
1996, Rundqvist et al. 1997, & Mitoff et al. 2011). Most commonly, plasma NE is measured 
to assess SNS activity because it depends on the rate of immediate NE reuptake and clearance 
from the circulation (Esler et al. 1990). In CHF however, there is defective neuronal 
catecholamine reuptake that may result in accumulation of large amounts of NE in the cardiac 
sympathetic neuroeffector junctions (Liang et al. 2007). In normal conditions NE transporters 
(NET) recapture and remove more than 90% of these large amounts of NE into the 
sympathetic terminals (Eisenhofer et al. 1996, & Cingolani et al. 2011). However, in CHF the 
NET loses its function which results in decreased NE stores, NE extraneuronal clearance, and 
contractile impairments (Cingolani et al. 2011).  
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Table 1.2: Gender effects on sympathetic nervous system induced progression to heart failure  
Human studies 
Author  Technique Markers of SNS activation  Findings & Conclusion  
Mitoff et al. 2011 Radiotracer, NE 
spillover 
NE in coronary sinus plasma Higher NE concentrations in women than in men with HF. 
Therefore, women have increased cardiac-specific sympathetic 
activation.  
Aroson et al. 2000 Heart rate variability 
(HRV) analysis 
Heart rate activation HRV was higher in females with HF compared with males with 
HF. Therefore, females in HF have increased parasympathetic 
activation, whereas males in HF have increased sympathetic 
activation.  
Animal studies 
Author  Technique Markers of SNS activation Findings & Conclusion  
Gao et al. 2003  Over-expression of β-
adrenergic receptors 
 
β2-adrenergic receptors 
 
Male mice showed LV dilatation & pump dysfunction, but 
improved with castration compare to female mice. Therefore, 
greater survival in female transgenic mice vs. male mice.  
Dash et al. 2003 Phospholamban, (PLB) 
overexpression= 
increase  NE 
NE-mediated p38 MAPK 
activation 
 
Early p38 MAPK activation in TG Males & delay in TG female. 
Therefore, females exhibit a temporal delay for contractile 
dysfunction & hypertrophy. Oestrogen modulates MKP-1 
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 expression which inhibits MAPK activation.    
Dent et al. 2010 
 
Volume overload, AV 
shunt 
Plasma catecholamines, β-
AR affinity, AC activity 
Increased catecholamines in males from AV shunt may account 
for the greater increase in cardiac output and higher degree of 
cardiac hypertrophy.  
Dent et al. 2012 
 
Volume overload, AV 
shunt 
Plasma catecholamines, β-
AR content, AC content 
Decreased β1-ARs & β2-ARs in AV shunt males and 
ovariectomized females, but increased in sham females and those 
that underwent oestrogen therapy. AV shunt female rats maintain 
cardiac function because of sex-hormones. 
Hodson et al. 2014 ISO β-AR activation ISO caused cardiac dilatation, but not pump dysfunction in both 
castrated and non-castrated male rats. Therefore, castration does 
not influence the extent of LV dilatation. 
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Importantly, gender appears to play a role in NET function. Indeed, Buonanno et al. 1982 
demonstrated that blockade of NET with reboxetine in 12 healthy men may result in a greater 
increase in cardiac stroke volume and cardiac output than in 12 age-matched women. 
Therefore, suggesting that the male heart depends on NET more than the female heart. 
Gender-related studies that assess cardiac-specific sympathetic activity in patients with heart 
failure are limited. There is only one study (Mitoff et al. 2011) that incorporated patients with 
CHF (Table 1.2). Mitoff et al. 2011 studied 166 subjects: 48 with normal heart function and 
118 with CHF but stable symptoms and left ventricle (LV) ejection fraction <35%. This study 
(Mitoff et al. 2011) demonstrated that patients with CHF have NET dysfunction. Importantly, 
this study confirmed that women have reduced NET function compared to men with or 
without HF. Therefore, it is clear in this regard that females have attenuated SNS activity 
compared to males. 
Moreover, animal studies have documented gender-related differences in HF induced 
by SNS activation (Gao et al. 2003, Dash et al. 2003, Dent et al. 2010, & Dent et al. 2012) 
(Table 1.2). In this regard, several studies have shown the effects of gender on HF associated 
with increased SNS activity in response to volume overload (Dent et al. 2010, & Dent et al. 
2012). Recently, in our laboratory we have demonstrated that castration in male Sprague 
Dawley rats does not prevent systolic chamber dysfunction after chronic β-adrenergic 
activation (Hodson et al. 2014). In contrast, another study suggests that castration offers 
protective effects against increases in LV diameters in transgenic mice with cardiac β2-AR 
overexpression (Gao et al. 2003). In a study using transgenic mice with fourfold 
phospholamban (PLB) expression, gender differences in cardiomyopathy or hypertrophy 
induced by SNS activation were noted (Dash et al. 2003). This study (Dash et al. 2003) 
demonstrated that transgenic male mice exhibited earlier signs of progressive HF than their 
counterpart transgenic female mice. Moreover, ovariectomy did not offer cardioprotective 
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effects to β-adrenergic responsiveness in the hearts of ovariectomised female mice compared 
to the hearts of sham female mice and male mice (McIntosh et al. 2011). Similar evidence 
was demonstrated in Sprague Dawley rats after volume overload induced by arteriovenous 
shunt that the cardiac function was maintained in the sham female rats and the female rats 
which underwent oestrogen-replacement after ovariectomy compared with the male rats and 
ovariectomized female rats (Dent et al. 2012). These data suggest that oestrogen is 
responsible for maintaining cardiac function. 
To my knowledge, the above mentioned studies are the only existing evidence of 
gender-related differences in HF induced by SNS activation. A summary of these studies is 
therefore provided in table 1.2. Importantly, from the existing animal studies in table 1.2 it is 
evident that none of these studies investigated the influence of gender on SNS activation and 
the progression to HF in a hypertensive animal model (Spontaneously Hypertensive Rats, 
SHRs).  
Therefore, the aim of my study was to investigate the influence of gender on SNS-
induced alterations in cardiac remodeling and function in Spontaneously Hypertensive Rats 
as discussed below. 
 
1.8 Aim 
To investigate the role of gender in the transition from compensated cardiac hypertrophy 
to heart failure using a model of adrenergic-induced cardiac dilatation and pump dysfunction in 
hypertensive rats. 
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1.9 Objectives 
The primary objective of the current study was therefore to determine whether 
hypertensive female rats are less susceptible than hypertensive male rats to cardiac dilatation 
and pump dysfunction produced by long-term β-adrenergic receptor (AR) activation.  
The secondary objective of the current study was to determine whether apoptosis or 
necrosis are possible mechanisms of gender differences in cardiac dilatation and pump 
dysfunction produced by β-adrenergic receptor (AR) activation.  
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Chapter Two - Materials and Methods 
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2. Study designs 
For purposes of addressing the objectives of this dissertation, two studies were subsequently 
conducted; namely the long term and short term beta adrenergic receptor stimulation studies (see 
sections 2.1 & 2.3, respectively). The long term beta adrenergic receptor stimulation focused on the 
primary objective. Subsequently, the short term beta adrenergic receptor stimulation was to assess a 
possible mechanism responsible for beta adrenergic receptor stimulation induced gender-related 
differences on cardiac remodeling and function in Spontaneously Hypertensive rats. Each study 
design is thoroughly described in the subsequent subheadings.            
2.1 Experimental protocol for the long-term β-adrenergic receptor stimulation study 
The animal model of hypertensive heart disease studied was the Spontaneously Hypertensive 
Rat (SHR). SHRs were obtained at the age of nine months from the Central Animal Services of the 
University of the Witwatersrand. Premature cardiac dilatation and pump dysfunction was induced in 
SHR by chronic β-adrenergic receptor activation (β-AR), using a method established in our laboratory 
and previously described (Tsotetsi et al. 2001, Badenhorst et al. 2003, & Veliotes et al. 2005). A total 
of 30 male rats and 27 female rats were randomly assigned to four groups (Figure 2.1). Rats from two 
groups, 1 female group and 1 male group, received daily subcutaneous injections (0.1ml) of 
isoproterenol (ISO), a β-AR agonist, at the dose of 0.04 mg.kg-1 for 6 months, as previously described 
(Veliotes et al. 2005). Rats from the other two groups, 1 female group and 1 male group, received 
daily subcutaneous injections of the saline vehicle (0.1 ml of 0.9 % saline solution) for 6 months. For 
the duration of the study the rats were housed in the Central Animal Services of the University of the 
Witwatersrand (2 rats per cage, minimum). To reduce the number of potential deaths from 
arrhythmias, rats were habituated to gradually increasing doses of ISO (1
st
 week 0.01 mg.kg
-1
.day
-1
, 
2
nd
 week 0.02 mg.kg
-1
.day
-1
, 3
rd
 week 0.03 mg.kg
-1
.day
-1
, 4
th
week 0.04 mg.kg
-1
.day
-1
). Rats in the 
saline group received daily injections of (0.1ml) of the saline vehicle for 2 weeks. Nevertheless, six 
rats, 2 females and 4 males, died due to arrhythmias towards the end of the experiments; all received 
chronic β-adrenergic receptor activation. 
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Figure 2.1: Summary of rat groups in the long-term β-adrenergic receptor stimulation 
study. 
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2.2 Cardiac structure and function: 
2.2.1 Echocardiography: 
Cardiac structure and function were assessed in vivo using two-dimensional directed M-
mode echocardiography as previously described (Tsotetsi et al. 2001, & Veliotes et al. 2005). 
Left ventricular chamber dimensions and wall thickness were determined in systole and 
diastole by an experienced investigator blinded to the experimental groups, 24 hours after the 
last dose of isoproterenol or saline solution. Rats were anaesthetized with ketamine (75 
mg.kg
-1
) and xylazine (15 mg.kg
-1
) 15 minutes before the procedure. The chest of the rats was 
shaved and an ultrasonic probe was placed on the chest of the animal to obtain M-mode 
images in systole and diastole. For the duration of three consecutive beats, the internal 
dimensions and wall thickness of the left ventricle were measured in systole and diastole 
(Figure 2.2). Relative wall thickness (RWT), Left ventricular endocardial (FSend) and midwall 
(FSmid) fractional shortening were then calculated (see equations below). FSend and FSmid 
were employed as measures of chamber and myocardial systolic function respectively. 
 FSend = (LV EDD-LV ESD)/LV EDD x 100 
Where LV EDD = left ventricular end diastolic internal diameter and LV ESD = left 
ventricular end systolic internal diameter. 
 FSmid = [(LV EDD+LVED PWT)-(LV ESD+LVES PWT)]/(LV EDD +LVED PWT) 
x 100 
Where LVED PWT = left ventricular end diastolic posterior wall thickness and LVES PWT 
= left ventricular end systolic posterior wall thickness. 
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Figure 2.2: Representative example of an M-mode echocardiographic image of the left 
ventricle in a Spontaneously Hypertensive Rat. A, left ventricular end diastolic diameter 
(LV EDD); B, left ventricular end systolic diameter (LV ESD); C, left ventricular end 
diastolic posterior wall thickness (LVED PWT); D, left ventricular end systolic posterior wall 
thickness in systole (LVES PWT).  
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 Relative wall thickness = LVED PWT/(EDD/2) 
Where LVED PWT = left ventricular end diastolic posterior wall thickness. 
2.2.2 Blood pressure measurement: 
After echocardiography, but still under anaesthesia an incision was made on the left 
side of the rat’s neck. The left carotid artery was clamped and an incision in the left corotid 
artery was made for insertion of a catheter connected to a fluid filled Statham P23 pressure 
transducer. The clamp was removed and systolic and diastolic blood pressures were recorded 
under anaesthesia. 
2.2.3 Isolated perfused heart preparations: 
15-20 minutes after the administration of ketamine and xylazine (after 
echocardiography and blood pressure measurement), rats were euthanized by thoracotomy 
and the heart removed from the thoracic cavity. Excised hearts were placed in an ice-cold 
physiological saline solution, then weighed and mounted on an isolated perfused heart 
apparatus and load-independent measures of cardiac function and dimensions were then 
determined by an experienced investigator as previously described by our group (Tsotetsi et 
al. 2001, & Veliotes et al. 2005). Hearts were retrogradely perfused at a constant flow with a 
37°C filtered physiological saline solution consisting of (in mM) 118.0 NaCl, 4.7 KCl, 2.5 
CaCl2, 25.0 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4 and 10.0 glucose with a pH of 7.4. The 
solution was saturated with 95% O2 and 5% CO2 gas and filtered through a size 0.45μm 
Millipore Durapore membrane filter. Hearts were paced at 330-360 beats.min
-1
 with platinum 
electrodes attached to the left atrium and the apex of the heart. An empty latex balloon with a 
known wall volume (empty volume of 0.11 ml), coupled to a Statham P23 pressure 
transducer and a micromanipulator, was inserted through the mitral valve into the left 
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ventricular lumen (Figure 2.3 upper panel). The coronary flow rate was determined 
volumetrically and adjusted to achieve a flow of 12 mL.min
-1
.g of the wet heart weight. Left 
ventricular pressure, developed at incremental volumes, was recorded by a water-filled 
balloon-tipped cannula attached to a pressure transducer (Figure 2.3 lower panel). The 
volume of the balloon wall was measured with a water-displacement technique, and the same 
balloon was used throughout each study. A micromanipulator was used to gradually increase 
LV volumes to values that resulted in no further change in LV developed pressure (LV 
systolic minus diastolic pressure). LV pressures were determined at as many multiple small 
increments in volume as were practically possible to improve on the accuracy of curve fitting 
during analysis (Figure 2.4 left panel). From these data, left ventricular diastolic and systolic 
(developed) pressure-volume relations were derived to assess the extent of left ventricular 
dilatation and systolic chamber function respectively (Figure 2.4 right panel).  
2.2.3.1 Intrinsic systolic myocardial function: 
 
Intrinsic systolic myocardial function was determined from the slope of the systolic 
developed stress-strain relationship (myocardial systolic elastance-En) (Norton et al. 2002, 
Badenhorst et al. 2003b, & Veliotes et al. 2005). By calculating (from pressures and volumes) 
systolic stress and strain data, the impact of alterations in left ventricular chamber geometry 
on systolic function were eliminated (Weber et al. 1988). Left ventricular systolic stress and 
strain were calculated from previously described formulae (Weber et al. 1988a, & Norton et 
al. 2002) assuming a thick-walled spherical geometry of the left ventricle as follows: 
 
  
 
  
 
 
Left ventricular systolic stress = 1.36 x LV developed pressure x (LVV)
2/3
 
                                                             [LVV + (0943 x LV mass)]
2/3
 – LVV2/3 
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Figure 2.3: Representative example of the experimental setup for the isolated perfused 
heart apparatus. A, the fluid filled catheter connected to the balloon in the left ventricle 
lumen; B, platinum electrodes attached to the isolated heart; C, the micromanipulator; D, the 
pressure transducer  
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Figure 2.4: Diagrammatic example of derived diastolic and systolic (developed) 
pressure-volume curves (right panel). Representative example of typical recordings 
obtained for diastolic and systolic pressures in isolated, perfused heart preparations 
(left panel). 
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Where LVV is left ventricular volume and LV V0 is the volume intercept of the LV 
developed pressure- volume relationship, i.e. LV volume when LV developed pressure = 0 
mm Hg. 
 
2.3 Experimental protocol for the short-term β-adrenergic receptor stimulation study: 
As both cardiomyocyte apoptosis and necrosis occur with short-term β-adrenergic 
receptor stimulation (Goldspink et al. 2004), in the present study the impact of gender on 
cardiomyocyte apoptosis and necrosis induced by short-term β-adrenergic receptor 
stimulation was assessed. The SHRs were obtained at the age of nine months. A total of 14 
male rats and 14 female rats (1 female rat died due to injection of ISO) were randomly 
assigned to four groups (figure 2.5). Habituation was done in one week by gradually 
increasing isoproterenol (ISO) doses to 0.04 mg.kg
-1 
every 2 days. Following habituation, rats 
from two groups received daily injection of isoproterenol (ISO) for a week. Rats from the two 
other groups received daily injections of the saline vehicle for a week (figure 2.5). 
 
2.4 Myocardial cellular changes responsible for HF: 
Whole hearts, left ventricle and right ventricle were weighed. The free wall of the right 
ventricle was trimmed off the septum of the heart and weighed; subsequently, the left ventricle 
with the septum was then weighed. The body weight and tibial length were measured to 
account for variations in the growth of rats. All the tissue samples were stored at -70°C for 
histology and cell damage (TUNEL staining and pathological scores) assessments. 
 
 
Left ventricular systolic strain =    LVV
1/3
 + [LVV + (0.943 x LV mass)]
1/3
] -1 
                                                             [LV V0
1/3
 + [LV V0 + (0.943 x LV mass)]
1/3
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Figure 2.5: Summary of rat groups in the short-term β-adrenergic receptor stimulation 
study. 
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2.4.1 Cardiomyocyte necrosis: 
As previously described by our group (Veliotes et al. 2005, Woodiwiss et al. 2001, & 
Badenhorst 2003), cardiomyocyte necrosis was assessed. A longitudinal slice of the left 
ventricle from the apex to the base through both the anterior and posterior left ventricular 
walls was obtained from all hearts and stored in formalin for subsequent histology. The left 
ventricular slice was processed for light microscopy and 5 μm-thick sections were cut 
through the wall thickness of the left ventricle. The sections were stained with Van Gieson 
which stains for fibrosis tissue a pink colour. The degree of myocyte necrosis was determined 
on each slice, where grade 0 indicates no histological evidence of fibrosis, grade 1 and 2 
respectively indicate patchy fibrosis in less or more than 20% of the field, grade 3 and 4 
respectively indicate diffuse contiguous subendocardial fibrosis in less or more than 50% of 
the field, and grade 5 and 6 respectively indicate full thickness (transmural) fibrosis in less or 
more than 50% of the field (figure 2.6). 
2.4.2 Cardiomyocyte apoptosis: 
As previously described by our group (Veliotes et al. 2005, & Badenhorst 2003), 
cardiomyocyte apoptosis was also assessed. The degree of apoptosis was quantified on 
myocardial tissue sections obtained from the same tissue blocks as used to assess the 
pathological score (Veliotes et al. 2005). Five μm thick sections were stained with a non-
radioactive in situ apoptotic cell death detection kit (DeadEndTM Colorimetric TUNEL 
system, Promega, Madison, WI, USA). Nuclear deoxyribonucleic acid (DNA) fragments in 
the tissue sections were detected using terminal deoxynucleotidyltransferase (TdT) to 
incorporate biotinylated nucleotide at the 3’-OH DNA ends. Horseradish-peroxidase-labeled 
streptavidin binds to biotinylated nucleotides and subsequently stains dark brown in response 
to hydrogen peroxide and diaminobenzidine. Both positive (DNase treated) and negative (no   
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Figure 2.6: Representative myocardial tissue sections stained with Van Gieson’s stain 
for necrosis. a, pink indicates necrotic section.  
  
a 
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addition of TdT) control tissue sections were incorporated into each assay. The number of 
apoptotic cardiomyocyte nuclei and the total number of cardiomyocyte nuclei (haematoxylin 
and eosin stain) in each slide were counted on ten evenly spaced fields from the apex to the 
base, using a computer-based image acquisition and analysis system at 200 times 
magnification (Axiovision 3, Carl Zeiss, Gottingen, Germany) (refer to figure 2.7). Apoptotic 
total cardiomyocyte nuclei were expressed as a percentage of the total number cardiomyocyte 
nuclei, refer to formula below. 
  
 
             
 
 
2.5 Data analysis 
A two-way analysis of variance (ANOVA) followed by Tukey-Kramer post hoc analysis 
was performed to determine differences in cardiac weights, left ventricular diameters and 
dimensions and systolic and diastolic function between the groups. A two-way ANOVA was 
also employed to determine differences in cardiomycyte apoptosis and pathological score. The 
level of significance was set at P<0.05. All statistical analysis was performed using GraphPad 
Prism 5 (Graph-pad Software Inc., San Diego, USA). All data are expressed as means±SEM.  
  
Apoptosis (%) =  Apoptotic cardiomyocyte nuclei 
                           Total number of cardiomyocyte nuclei   
X 100 
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Figure 2.7: Representative examples of cardiac tissues sections stained with 
haemotoxylin and eosin (A) and TUNEL (B & C) after 1 week of injection with 
isoproterenol (200X magnification microscope). (A) H & E stained section, (a) indicates 
cardiomyocyte nuclei (200X magnification microscope); (B) TUNEL positive tissue section 
indicating numerous cardiomyocyte apoptotic nuclei (200X magnification microscope); (C) 
TUNEL tissue section indicating only one nucleus, (a) indicates apoptotic cardiomyocyte 
nucleus (400x magnification microscope). 
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Chapter Three - Results 
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3.1 Effects of long-term β-adrenergic receptor stimulation and gender on body weights, 
heart weights and blood pressures. 
 
Table 3.1 shows the effects of gender and long-term β-adrenergic receptor stimulation 
on body and heart weights. At 15 months, male rats were heavier than female rats (p<0.0001) 
and tibial lengths were longer in the male rats compared to the female rats (p<0.0001). Heart, 
left ventricle and right ventricle weights were also greater in the male rats compared to the 
female rats (p<0.0001, p<0.0001 and p=0.0002, respectively). As a consequence of the 
relatively larger body weights in the male rats, the ratios of heart, left ventricle and right 
ventricle weights to body weight were lower than in the female rats. Isoproterenol 
administration had no effects on body weight in either male or female rats. However, 
isoproterenol administration resulted in increased heart, left ventricular and right ventricular 
weights in male rats but not in female rats. The systolic blood pressure values were similar in 
all the groups (mean±SEM, mm Hg; Male Sal: 126.0±10.6; Male Iso: 134.0±8.8; Female Sal: 
136.6±6.6; Female Iso: 119.3±4.7; p>0.05). The diastolic blood pressure values were also 
similar in all the groups (mean±SEM, mm Hg; Male Sal: 87.1±6.4; Male Iso: 88.8±5.9; 
Female Sal: 89.0±5.4; Female Iso: 79.7±4.1; p>0.05). 
 
3.2 Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular dimensions in vivo 
Table 3.2 and figure 3.1 show the effects of long-term β-adrenergic receptor stimulation 
and gender on left ventricle dimensions, in vivo. Left ventricular end diastolic diameter 
(figure 3.1), left ventricular end systolic diameter and posterior wall thickness in systole 
(table 3.2) were greater in the male rats compared to the female rats (p<0.0001, p=0.0004 and  
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Table 3.1: Effects of long-term β-adrenergic receptor stimulation on body, heart, left 
ventricular, right ventricular weights in male and female SHRs. 
BW, body weight; TL, tibial length; HW, heart weight; LVW, left ventricular weight; RVW, 
right ventricular weight; Sal, saline; Iso, isoproterenol. Data are expressed as means ± SEM. 
* p<0.05 vs female rats. † p<0.05 vs other groups (two-way ANOVA). 
       
 
     Male    Female 
Sal 
n=13 
Iso 
n=13 
Sal 
n=13 
Iso 
n=12 
Body weight (g) 379 ± 5.55* 384 ± 4.71* 221 ± 3.05 221 ± 4.33 
Tibia length (mm) 42.0 ± 0.47* 42.1 ± 0.64* 36.5 ± 0.36 37.4 ± 0.46 
 Heart weight (g)    1.46 ± 0.04* 1.64 ± 0.04*† 1.15 ± 0.07 1.06 ± 0.03 
Left ventricular weight (g) 1.16 ± 0.02* 1.26 ± 0.03*† 0.89 ± 0.04 0.81 ± 0.02 
  Right ventricular weight (g) 0.27 ± 0.01*   0.30 ± 0.02*† 0.22 ± 0.02 0.21 ± 0.01 
   HW/BWx100 0.39 ± 0.04* 0.43 ± 0.04* 0.52 ± 0.13 0.48 ± 0.03 
   LVW/BWx100 0.30 ± 0.02 * 0.34 ± 0.02 * 0.37 ± 0.02 0.41 ± 0.09 
   RVW/BWx100 0.07 ± 0.01* 0.08 ± 0.02* 0.10 ± 0.03 0.09 ± 0.02 
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Table 3.2: Effects of long-term β-adrenergic receptor stimulation on left ventricular 
dimensions as assessed in vivo in male and female SHRs. 
 
LV, left ventricle; ESD, end systolic diameter; PWED, posterior wall thickness at end 
diastole; PWES: posterior wall thickness at end systole; Sal, saline; Iso, isoproterenol. Data 
are expressed as means ± SEM.* p<0.05 vs female rats. †p<0.05 vs other groups (two-way 
ANOVA). 
  
 
       Male     Female 
Sal 
n=13 
Iso 
n=13 
Sal 
n=13 
Iso 
n=12 
LV ESD (mm)             3.26 ± 0.17* 4.33 ± 0.24*† 3.01 ± 0.23 3.01 ± 0.14 
PWED (mm) 2.31 ± 0.11  2.13 ± 0.06 2.10 ± 0.06 2.12 ± 0.05 
PWES (mm) 3.08 ± 0.08* 2.93 ± 0.06*† 2.68 ± 0.06 2.78 ± 0.06 
Relative 
wall thickness 
0.72 ± 0.05 0.56 ± 0.01† 0.70 ± 0.02 0.68 ± 0.02 
   50 
 
Sal Iso Sal Iso
0
5
7
9
L
V
E
D
D
 (
m
m
)
†
Male Female
*
*
n =         13         13                   13          12
 
Figure 3.1: Effects of long-term β-adrenergic receptor stimulation on left ventricular 
end diastolic diameter (LVEDD) in male and female SHRs. Data are expressed as 
means±SEM. LVEDD, left ventricular end diastolic diameter; Sal, saline; Iso, isoproterenol.* 
p<0.05 vs female rats. † p<0.05 vs other groups (two-way ANOVA). 
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p=0.0002, respectively). Six months of isoproterenol administration increased left ventricular 
end diastolic (p=0.0242), and end systolic (p=0.0123) diameters in male rats, but not in 
female rats. In addition, isoproterenol resulted in a decrease in posterior wall thickness at end 
systole and in relative wall thickness (p=0.0364) (table 3.2) in the male rats but not in the 
female rats. 
 
3.3 Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular chamber dimensions ex vivo 
 
Figure 3.2 shows left ventricular diastolic pressure-volume relations assessed using an 
isolated perfused heart system (upper panel) and the volume intercept at 0 mm Hg (lower 
panel) calculated from the left ventricular diastolic pressure-volume relations (left ventricular 
chamber volume). The left ventricular chamber volumes were greater in the male compared 
to the female rats (p<0.0001). Six months of isoproterenol administration resulted in a right 
shift in the left ventricular end diastolic pressure-volume relations in the male rats but not in 
the female rats. Consequently, the left ventricular chamber volume was increased in the male 
rats receiving isoproterenol compared to the other groups (p=0.004).      
 
3.4 Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular systolic chamber function 
 
Figure 3.3 shows left ventricular systolic chamber function as indexed by endocardial 
fractional shortening (FSend) determined using in vivo measurements (echocardiography). At  
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Figure 3.2: Effects of long-term β-adrenergic receptor stimulation on left ventricular 
chamber volumes as indexed by diastolic pressure-volume relations (upper panel) and 
the volume intercept at 0 mm Hg [V0] (lower panel) in male and female SHRs. Iso, 
isoproterenol; Sal, saline. Data are expressed as means ± SEM. LV V0, left ventricular 
volume intercept at 0 mm Hg; * p<0.05 vs female rats.† p<0.05 vs other groups (two-way 
ANOVA).  
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15 months, no difference (p=0.0819) in FSend was observed between the male and female rats. 
Also, isoproterenol administration had no effect on FSend in either male or female rats 
(p=0.4891). Figure 3.4 shows left ventricular systolic chamber function as indexed by load-
independent systolic pressure-volume relations (upper panel) and the slope of these relations 
[left ventricular end systolic elastance, LV Ees] (lower panel) determined using ex vivo 
isolated perfused heart preparations. Gender had no effect on LV Ees. Isoproterenol decreased 
LV Ees in the male rats (p=0.0474) but not in the female rats (p>0.05).  
 
3.5 Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular intrinsic myocardial systolic function 
 
Figure 3.5 shows left ventricular intrinsic midwall fractional shortening (FSmid) 
determined in vivo using echocardiography. At 15 months, FSmid was greater in the female 
compared to the male rats (p=0.03777). No difference in FSmid was observed between the 
different groups of male and female rats that received isoproterenol or saline (p=0.8532). 
Figure 3.6 shows left ventricular intrinsic myocardial systolic function as indexed by left 
ventricular systolic stress-strain relations (upper panel) ex vivo. The lower panel shows the 
slope (left ventricular end systolic myocardial elastance - LV En) of the left ventricular 
systolic stress-strain relations. LV En was decreased in male compared to female rats 
(p=0.0190), but no ISO effect noted. 
  
   54 
 
Sal Iso Sal Iso
0
20
30
40
50
60
F
S
e
n
d
 (
%
)
Male Female
n =         13         13                   13          12
 
Figure 3.3: Effects of long-term β-adrenergic receptor stimulation on left ventricular 
systolic chamber function as indexed by endocardial fractional shortening (FSend) in 
male and female SHRs. Iso, isoproterenol; Sal, saline. Data are expressed as means ± SEM. 
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Figure 3.4: Effects of long-term β-adrenergic receptor stimulation on left ventricular 
systolic chamber function as indexed by pressure-volume relations. Iso, isoproterenol; Sal, 
saline. Data are expressed as means ± SEM. †p<0.05 vs other groups (two-way ANOVA). 
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Figure 3.5: Effects of long-term β-adrenergic receptor stimulation on left ventricular 
intrinsic myocardial systolic function as indexed by midwall fractional shortening (FSmid) 
in male and female Spontaneously Hypertensive Rats. Iso, isoproterenol; Sal, saline. Data are 
expressed as means ± SEM. *p<0.05 vs female rats. 
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Figure 3.6 : Effects of long-term β-adrenergic receptor stimulation and gender on left 
ventricular intrinsic myocardial systolic function as indexed by LV systolic stress-strain 
relations (upper panel). The lower panel shows the slope (LV end systolic myocardial 
elastance-LV En) of the left ventricular systolic stress-strain relations in male and female 
Spontaneously Hypertensive Rats. Iso, isoproterenol; Sal, saline. Data are expressed as means 
± SEM. * p<0.05 vs female rats. 
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3.6 Effects of short-term β-adrenergic receptor stimulation and gender on body, heart, 
left and right ventricular weights 
Table 3.3 shows the effects of short-term β-adrenergic receptor stimulation and gender 
on body, heart, left and right ventricular weights. At 15 months, the body and heart weights 
were heavier in the male rats compared to the female rats (p<0.0001). Heart weights were 
heavier in both the male and female rats that received isoproterenol for a week (p<0.05). The 
ratios of heart, left ventricle and right ventricle weights to body weight were lower in the 
male than female rats. 
 
3.7 Effects of short-term β-adrenergic receptor stimulation and gender on necrosis and 
apoptosis 
Figure 3.7 shows the effects of short-term β-adrenergic receptor stimulation on 
pathological score (necrosis) shown in the upper panel and apoptotic cardiomyocytes (lower 
panel). After one week of daily isoproterenol (ISO) administration, there was no difference in 
pathological score and apoptosis of cardiomyocytes between the different experimental 
groups. However, there was a noticeable trend for ISO effect on apoptosis (p=0.08). 
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Table 3.3: Effects of short-term β-adrenergic receptor stimulation on body, heart, left 
and right ventricular weights in male and female SHRs. 
 
BW, body weight; HW, heart weight; LVW, left ventricular weight; Sal, saline; Iso, 
isoproterenol. Data expressed as means ± SEM.*p<0.05 vs female rats. † p<0.05 vs other 
groups (two-way ANOVA). 
 
  
 
Male Female 
Sal Iso Sal Iso 
Body weight(g) 370.0 ± 2.27*  352.9 ± 3.63* 223.7 ± 1.59  215 ± 1.88 
Heart weight (g)    1.38 ± 0.02*  1.52 ± 0.02*† 0.96 ± 0.02 1.02 ± 0.01† 
Left ventricular weight (g) 1.02 ± 0.01* 1.12 ± 0.02* 0.72 ± 0.02 0.75 ± 0.004 
 Right ventricular weight (g) 0.29 ± 0.01* 0.29 ± 0.01* 0.19 ± 0.004 0.18 ± 0.03 
 HW/BW*100 0.37 ± 0.01* 0.43 ± 0.01* 0.46 ± 0.02 0.48 ± 0.01 
 LVW/BW*100 
0.28 ± 0.01* 0.32 ± 0.01* 0.34 ± 0.01  0.35 ± 0.01 
 RVW/BW*100 
0.08 ± 0.01* 0.08 ± 0.01*  0.082 ± 0.005 0.083 ± 0.004 
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Figure 3.7: Effects of short-term β-adrenergic receptor stimulation on pathological 
score (necrosis) shown in the upper panel and apoptotic cardiomyocyte (lower panel) in 
male and female Spontaneously Hypertensive Rats. Iso, isoproterenol; Sal, saline. Male 
Sal (n=7); Male Iso (n=7); Female Sal (n=7); Female Iso (n=6). Data expressed as means ± 
SEM. 
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Chapter Four - Discussion 
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4.1 Main findings of the present study 
The main findings of the present study are as follows: Chronic (six months) β-
adrenergic receptor (β-AR) stimulation produced left ventricular hypertrophy (LVH) 
associated with cardiac dilatation in the male Spontaneously Hypertensive Rats (SHRs), but 
not in the female SHRs as determined in vivo by an increase in the left ventricular dimension, 
a decrease in the relative wall thickness, and ex vivo by a right shift in the volume intercept at 
0 mm Hg pressure (V0) of the left ventricular diastolic pressure-volume relationship. 
Moreover, chronic β-AR stimulation produced pump dysfunction in the male SHRs, but not 
in the female SHRs as determined ex vivo by a decrease in the left ventricular systolic 
chamber function (end systolic elastance, LV Ees). However, chronic β-AR stimulation did 
not impact on the myocardial systolic function when assessed both in vivo (systolic midwall 
fractional shortening, FSmid) and ex vivo (systolic myocardial elastance, LV En) in both male 
and female SHRs.  
4.2 Uniqueness of current study 
This is the first study to assess in vitro the effects of gender on β-adrenergic induced 
cardiac remodeling and systolic pump dysfunction in SHRs. Previously, in our laboratory 
cardiac remodeling and function in SHRs exposed to the β-adrenergic stimulation has been 
extensively studied (Badenhorst et al. 2003b, Gibbs et al. 2004, & Veliotes et al. 2005). In 
these studies the SHRs were compared to Wistar Kyoto (WKY) rats, the original genetic 
normotensive strain. These studies have shown that the SHRs exposed to β-adrenergic 
stimulation developed progressive LVH associated with adverse ventricular remodeling 
(cardiac remodeling and pump dysfunction) earlier than SHRs not exposed to β-AR 
stimulation (Badenhorst et al. 2003b, & Gibbs et al. 2004). Therefore, these findings 
suggested that β-AR stimulation has a synergetic effect with pressure overload (hypertension) 
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to produce progressive LVH and adverse ventricular remodeling. There are limited studies 
that have assessed the effect of gender on cardiac remodeling and function in ageing SHRs 
(Pfeffer et al. 1982, Tamura et al. 1999, & Chan et al. 2011). Moreover, to my knowledge, 
there are no studies that have assessed the effect of gender on cardiac remodeling and 
function induced by chronic β-AR stimulation in a pressure overload animal model (SHRs). 
4.3 Comparisons with previous studies 
4.3.1 Gender influence on the progression from concentric left ventricular hypertrophy 
to dilatation  
The present study has assessed the impact of gender on the LVH associated with 
cardiac dilatation in hypertensive rats after chronic β-adrenergic activation. The results from 
the current study show that the heart, left ventricle and right ventricle weights are heavier in 
the male SHRs compared with the female SHRs after the administration of either 
isoproterenol or saline vehicle. However, after the heart, left and right ventricular weights had 
been corrected for 100g body weight to eliminate gender differences, the female rats showed 
increases in the heart, left ventricular and right ventricular weights compared to male rats that 
received either isoproterenol or saline vehicle. Therefore the gender differences in heart and 
ventricular weights are due to differences in body weight. 
 In response to chronic β-adrenergic activation, the male rats but not the female rats 
developed heavier hearts than the saline-administered male rats. Hence, only the male rats 
developed hypertrophy in response to β-adrenergic activation. Moreover, the reduced relative 
wall thickness and the increased left ventricular dimensions in the isoproterenol-administered 
male rats compared to the female rats indicate that the male, but not the female rats, 
developed cardiac dilatation. In support of the current study, a previous study demonstrated 
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that male mice after two weeks of pressure overload induced by aortic banding developed 
concentric hypertrophy as indicated by a higher heart weight to body weight ratio than the 
female mice (Skavdahl et al. 2005). Moreover, following 20 weeks of aortic banding in 
Wistar rats it was demonstrated that the male rats developed cardiac dilatation whereas the 
female rats maintained concentric hypertrophy (Douglas et al. 1998). These data support the 
present study which has shown that six-months of isoproterenol administration produced 
cardiac dilatation in the male SHRs, but not in the female SHRs.  
The influence of gender on left ventricular remodeling in healthy human conditions has 
previously been shown (Dannenberg et al. 1989, Lauer et al. 1991, & Levy et al. 1996). 
Importantly, the influence of gender on the characteristics of LVH and its progression to 
heart failure under pathological loading conditions has been reported in human and animal 
studies (Pfeffer et al. 1982, Topol et al. 1985, Carrol et al. 1992, Villari et al. 1992, Douglas 
et al. 1995, Douglas et al.1998, Tamura et al. 1999, Weinberg et al. 1999, Gardner et al. 
2002, Brower et al. 2003, Monasky et al. 2008, Petrov et al. 2010, & Chan et al. 2011). The 
findings of the current study are in agreement with other human and animal studies. The 
human studies have shown gender-related differences in the left ventricles of women patients 
exposed to chronic pressure overload by aortic stenosis and indeed, have shown that women 
have smaller, more concentric hypertrophied left ventricles with better systolic function 
performance, whereas men have larger, more eccentric hypertrophied ventricles with 
depressed systolic function (Topol et al. 1985, Carrol et al. 1992, Villari et al. 1992, & 
Douglas et al. 1995). It is suggested that the existence of concentric hypertrophy in the 
female subjects during hemodynamic overload normalizes left ventricular systolic function 
(Devereux et al. 1987, Carrol et al. 1992, Villari et al. 1992, Liebson et al. 1993, & 
Aurigemma et al. 1994). Although these studies are in agreement with the current study in 
that they report a preserved systolic function with concentric hypertrophy in the female hearts 
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compared to the male hearts, their data were only assessed in vivo. Hence, the data from 
previous studies may be influenced by heart rate and loading conditions. Moreover, Carrol et 
al. (1992) demonstrated that elderly women (>60 years old) under chronic pressure overload 
induced by aortic stenosis had higher relative wall thickness and better preservation of 
systolic left ventricular function compared to men. However, this study failed to consider the 
hormonal influences with ageing on cardiac hypertrophy as aging is associated with 
menopause in females (Pfeffer et al. 1979, & Scheuer et al. 1987). It should therefore be 
acknowledged that ageing and gender play key roles in the differences of left ventricular 
adaptation to systolic pressure overload. Nevertheless, a study by Villari et al. (1995) 
reported similar findings in young female patients exposed to chronic aortic stenosis. Indeed 
as in the elderly women, young women had concentric hypertrophy and better ventricular 
systolic function; compared to young male patients who presented with characteristics of 
eccentric hypertrophy with reduced myocardial contractility and a depressed systolic left 
ventricular function. Hence, irrespective of whether pre- or post-menopausal women were 
assessed, female gender appears to protect against pressure overload induced cardiac 
remodelling and systolic dysfunction. Nevertheless, these studies were all conducted in vivo 
and hence the results may be influenced by differences in heart rate and loading conditions. 
With respect to animal studies, studies in rodents have shown the effects of gender on 
the left ventricular adaptation to chronic pathological loading; including pressure (Pfeffer et 
al. 1982, Douglas et al. 1998, Tamura et al. 1999, & Jain et al. 2002) or volume (Gardner et 
al. 2002, & Dent et al. 2010) overload. Firstly, in vivo cardiac dimension assessments 
demonstrated that female SHRs (aged 6–18 months) had normal ventricular dimensions 
compared to the male SHRs which had ventricular dilatation at the age of 12 months (Pfeffer 
et al. 1982, & Tamura et al. 1999). In addition, Chan et al. (2011) demonstrated that male 
SHRs exhibited cardiac dilatation at the age of 15 months; whereas female SHRs showed 
   66 
 
signs of the ventricular dilatation only at the age of 18 months. In this regard, it is clear that 
the male SHRs have an early onset for ventricular dilatation compared to the female SHRs. 
Secondly, in Wistar rats and Dahl Salt-Sensitive (DSS) rats at 20 weeks after pressure 
overload induced by aortic banding or genetic hypertension respectively, the female rats were 
protected from ventricular dilatation and had maintained concentric hypertrophy compared to 
the male rats that showed ventricular eccentric hypertrophy (Douglas et al. 1998, & Jain et al. 
2002). Lastly, in Sprague-Dawley rats after volume overload induced by arteriovenous (AV) 
shunt, the male rats demonstrated LV dilatation and increased compliance compared to the 
female rats; whereas the female rats presented with left ventricular concentric hypertrophy 
(Gardner et al. 2002, Brower et al. 2003, Dent et al. 2010, & Dent et al. 2012). However, a 
study in isolated hearts from Wistar rats after 6 weeks of aortic banding (pressure overload) 
demonstrated that both the male and female hearts had a similar degree of hypertrophy 
(Weinberg et al. 1999). Clearly, it can be suggested that the transition to ventricular dilatation 
from ventricular hypertrophy depends largely on the duration of the pathologic loading. 
Furthermore, it should be noted that males exhibited an early onset for the transition from 
concentric LVH to dilatation. 
4.3.2 Gender influence on the progression to systolic dysfunction in response to pressure 
overload  
The present study has demonstrated that six months of β-adrenergic receptor 
stimulation to SHRs produced systolic dysfunction in the male rats, but not in the female rats 
as determined by a decrease in the left ventricular systolic chamber function ex vivo (end 
systolic elastance, LV Ees). Although, systolic chamber function in vivo (endocardial 
fractional shortening, FSend) failed to show differences in all the groups, however the 
decreased posterior wall thickening in systole in the male ISO group would suggest a 
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decreased systolic chamber function. Importantly, the in vivo systolic function assessment is 
load and heart rate dependent. In contrast to the current study, other studies have shown a 
change in in vivo systolic function with dilatation in either volume or pressure overload 
(Pfeffer et al. 1982, Douglas et al. 1998, Tamura et al. 1999, & Brower et al. 2003, Skavdahl 
et al. 2005, Dent et al. 2010, & Dent et al. 2012).  Whereas, the ex vivo systolic cardiac 
function assessment (LV Ees) is independent of load and heart rate. Therefore, compared to in 
vivo assessments, ex vivo assessments of systolic cardiac function are a more reliable 
technique, because these assessments allow for the exclusion of the influences of load and 
heart rate. The current study also demonstrated that six months of β-adrenergic receptor 
stimulation did not impact on myocardial systolic function when assssed both in vivo 
(systolic midwall fractional shortening, FSmid) and ex vivo (systolic myocardial elastance, LV 
En) in the male and female SHRs. 
 In addition, to the differential impact of β-adrenergic activation in male versus female 
rats a gender effect was noticed in the current study, whereby both in vivo and ex vivo 
assessments demonstrated that the female rats had a higher myocardial systolic cardiac 
function compared to the male rats. These data therefore suggest that β-adrenergic activation 
initiates the progression from concentric hypertrophy to cardiac dysfunction primarily 
through mechanism other than reductions in myocardial systolic cardiac function in male 
SHRs. Indeed, this notion was clarified be other researchers, whereby it was proposed by 
Cohn (1995), and subsequently substantiated by data obtained in human (Vasan et al. 1997) 
and animal (Norton et al. 2002, Badenhorst et al. 2003, & Osadchii et al. 2007) studies that 
pump dysfunction can occur mainly as a consequence of cardiac dilatation rather than 
myocardial contractile disturbances. Moreover, in Sprague Dawley rats three months of β-
adrenergic activation resulted in pump dysfunction as determined by decreased LV Ees but 
with no differences in myocardial systolic function as determined by LV En (Osadchii et al 
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2007). In addition, ageing SHRs demonstrated no changes in myocardial contractility despite 
cardiac dilatation and subsequently cardiac dysfunction in either male or female rats (Tamura 
et al. 1999, & Chan et al. 2011). In contrast to this concept, data from Sabbah (1998) 
suggested that cardiomyote apoptosis or necrosis may contribute to pump dysfunction and 
subsequently produce cardiac dilatation. We have shown that despite reductions in the 
myocardial contractility and cardiomyocyte apoptosis after three months of β-adrenergic 
activation, rats are still able to maintain myocardial contractility, possibly through the 
enhanced myocardial α-adrenergic receptor mediated contractile responses and as well as an 
increased presynaptic myocardial norepinephrine release (Osadchii et al 2007). In this regard, 
alterations in myocardial contractility can only be a consequence rather than a cause of pump 
dysfunction.  
Similar to the findings of the present study, human studies have shown in vivo that 
women have a higher systolic function compared to men in healthy individuals (Buonanno et 
al. 1982, & de Simone et al. 1991) and patients exposed to chronic pathological loading 
(Topol et al. 1985, Carrol et al. 1992, Villari et al. 1992, Aurigemma et al. 1994, Douglas et 
al. 1995, & Villari et al. 1995). In this regard, Devereux et al. (1998) reported that both 
normotensive and hypertensive women have an enhanced chamber function compared to 
men. In addition, evidence from elderly patients under pressure overload induced with aortic 
stenosis, also demonstrated that the systolic function is more often depressed in men than in 
women (Carroll et al. 1992, & Aurigemma et al. 1994). Moreover, young women with aortic 
stenosis demonstrated ventricular concentric hypertrophy with a normal to supernormal 
systolic function; whereas young men had a reduced systolic function (Villari et al. 1995).  
The gender-related differences in systolic function found in my study are also 
consistent with animal studies, which have also reported that female rats have an enhanced 
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systolic function compared to male rats when exposed to either pressure (Pfeffer et al. 1982, 
Weinberg et al. 1999, & Chan et al. 2011) or volume (Gardner et al. 2002, Brower et al 2003, 
& Dent et al. 2010) overload conditions. Moreover, in normal physiological conditions both 
male and female rats have the same systolic LV function, however under pressure overload 
this parameter is reduced in male rats but not in female rats (Monasky et al. 2008). In 
addition, studies of ageing SHRs have reported that male rats had systolic dysfunction that 
coincided with the structural progression to eccentric hypertrophy (Tamura et al. 1999, & 
Chan et al. 2011). Furthermore, ex vivo cardiac function assessments in Wistar rats have 
shown that the female rat hearts have a normal systolic function that was markedly reduced in 
the hearts of the male rats after pressure overload (Weinberg et al. 1999). Importantly, it is 
suggested that the enhanced myocardial contractility in female rats is attributed to a greater 
shortening of the papillary muscle than in the male rats (Capasso et al. 1983). This notion was 
also supported by Gao et al. (2003) in that female mice have a greater myocardial 
contractility in the absence of β-adrenergic activation, whereas male mice subjected to β-
adrenergic activation progress to systolic dysfunction. Therefore these studies suggest that a 
gender difference in myocardial contractility is largely attributed to the different activities in 
the mediators of myocardial contractility, including calcium and actinomyosin ATPase 
(Malhotra et al. 1981). In the male rats, delay in the rate of calcium release and reuptake 
result in decreased calcium activated actomyosin and myosin ATPase activity, and hence a 
depressed myocardial contractility (Capasso et al. 1983). 
In the current study the female SHRs had greater cardiac function and smaller end-
diastolic and systolic volumes, despite similar systolic and diastolic blood pressure values. It 
is unknown whether these differences result from intrinsic differences in the cardiomyocyte 
molecular adaptation to pressure overload between male and female rats or are related to 
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other factors extrinsic to the myocardium. Therefore, gender effects on cardiomyocyte death 
were assessed as a possible mechanism that may explain gender-related differences. 
4.3.3 Gender differences on cardiomyocyte apoptosis and necrosis  
It has been shown that β-adrenergic receptor stimulation induces cardiomyocyte 
apoptosis (Saito et al. 2000, Kim et al. 2006, & Osadchii et al. 2007). The current study failed 
to show gender differences in cardiomyocyte apoptosis after five days of ISO administration. 
However, it should be noted that there was a trend (p=0.08) for an ISO effect in both the male 
and female SHRs. In conjunction with the current study, previous work from our laboratory 
has shown that five days of β-adrenergic activation induces cardiomyocyte apoptosis in both 
the male and the female Wistar-Kyoto (WKY) rats (C.Mielke, MSc dissertation). 
Importantly, as the current study showed no gender differences in cardiomyocyte apoptosis, 
this suggests that cardiomyocyte apoptosis is not responsible for the differences in LV 
dimensions and systolic pump dysfunction between the males that received ISO and the other 
groups.  
The current study also failed to show gender differences in pathological scores 
(p=0.08), which are an index of necrosis. Hence, necrosis is also not responsible for the 
differences in LV dimension and systolic pump dysfunction between male and female rats 
receiving ISO. It is important to note, that the current study is the first study to our 
knowledge to evaluate the impact of gender on β-adrenergic receptor induced necrosis in 
SHRs. 
If neither apoptosis nor necrosis are responsible for the cardiac remodelling and 
dysfunction in male rats, what other factors could play a role. Several studies have reported 
that structural factors such as the collagen network of the ventricular wall are important 
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determinants of left ventricular systolic function in patients subjected to pressure overload 
(Doering et al. 1988, Krayenbuehl et al. 1989, Brilla et al. 1991, & Villari et al. 1993). 
Although not demonstrated in this study it is acknowledged that the collagen network plays a 
key role in the regulation and adaptation of left ventricular function under pressure overload 
conditions (Villari et al. 1993, & Woodiwiss et al. 2001). ISO-induced cardiac remodelling 
and dysfunction are associated with alterations in the characteristics of myocardial collagen 
(Woodiwiss et al. 2001, & Badenhorst et al. 2003). Moreover,  Villari et al. (1995) 
demonstrated that in 27 patients with aortic stenosis, 93% of all males and in 38% of all 
females had collagen disarrangement and myocardial dysfunction as determined in vivo. 
Therefore, it can be suggested that the collagen network arrangement may account for the 
gender-related differences in the left ventricular remodelling and function subjected to 
pressure overload.  
4.4 The potential clinical importance of the findings of the present study.  
The present study provides substantial evidence to indicate that in the settings of 
hypertension, males are more susceptible to the adverse effects of chronic adrenergic 
stimulation on LV cavity dimensions and systolic chamber function compared to females. 
Moreover, these data highlight the clinical significance of gender differences and the 
mechanistic cause for developing HF in hypertensive patients. However, there is still a need 
for a better understanding for the role of sex steroids in the development of heart failure 
through β-adrenergic stimulation and the presence of hypertension. At present, it can be 
suggested that different therapeutic strategies may need to be employed regarding HF in 
different hypertensive genders. A subsequent study should be conducted to assess the role of 
sex steroids in the development of heart failure in the presence of hypertension. Furthermore, 
other suggested mechanisms for the progressive HF should be employed in assessing the 
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gender differences in adverse cardiac remodelling mediated by β-adrenergic stimulation in 
the presence hypertension.  
4.5 Limitations 
The possible limitations to this study are as follows; firstly, there was a low sample size 
in each group for the short-term β-AR stimulation study. Although, there was a noticeable 
trend for an ISO effect compared to saline vehicle groups in both the male and the female 
SHRs, the low sample sizes failed to produce statistical power for an ISO effect in each 
gender. It may be easily assumed that with an increase in the sample size from each group a 
statistical significance for an ISO effect would have been attained. Nevertheless, the data 
clearly show no differences between male and female rats and hence rule out cardiomyocyte 
apoptosis as a mechanism for ISO-induced dilatation and pump dysfunction in the male rats. 
Secondly, the dose of ISO administered to these rats may have had less effect in females 
compared to males. There is debate in the literature regarding gender differences in cardiac β-
AR responsiveness. Studies in rat atrial and ventricular myocytes have shown that males 
show an enhanced β-adrenergic contractile response compared to females (Schwertz et al. 
1999, Vizgirda et al 2002, Curl et al. 2003, & McIntosh et al 2011). In contrast, other studies 
in isolated rat trabeculas (Monasky et al. 2008) and rat papillary muscle (Chu et al. 2005) 
reported no gender differences in β-adrenergic contractile responses. It is suggested that these 
difference may be due to the doses of ISO used. Moreover, McIntosh et al (2011) indicated 
that gender differences exist in the β-adrenergic contractile response at low doses of ISO. 
Therefore, the dose response study in isolated perfused male and female hearts of the SHR 
model can be performed to assess an appropriate dose for each gender. Nevertheless, if high 
dose of ISO is required in female rats compared to male rats, this would support the gender 
differences shown in the current study.  
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Conclusions 
In conclusion, as compared to female SHR, male SHR are more susceptible to the 
adverse effects of chronic β-AR activation on LV cavity dimensions and systolic chamber 
function. These results suggest that the higher prevalence of LV dilatation and systolic 
chamber dysfunction in males than in females with LVH may be attributed to an increased 
susceptibility to the adverse effects of β-adrenergic stimulation in males. The latter is 
important as it sheds light for the impact of gender on β-adrenergic-induced cardiac dilatation 
and systolic dysfunction in SHRs. Therefore, subsequent studies should be conducted to 
assess the impacts of castration and ovariectomy on β-adrenergic-induced cardiac dilatation 
and systolic dysfunction in SHRs.  
Future Studies 
As LVH is associated with diastolic dysfunction, I would suggest that future studies 
assess the impact of gender. Moreover, as there was no evidence to indicate that 
cardiomyocyte death was a mechanistic cause of cardiac dilatation in my studies, future 
studies should assess changes in fibrosis and collagen cross linkage as a possible cause of 
cardiac dilatation in this model.  
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